Chimeric immune activation proteins and use thereof
Fusion proteins combining chemokines and constitutively active immune sensor signaling pathway proteins enhance cancer treatment by inducing a robust type I interferon response, overcoming limitations of CAR-T therapies by targeting adjacent cancer cells.
Patent Information
- Application Number
- PCT/IL2026/050388
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Existing cancer therapeutics face challenges in effectively targeting and eradicating cancer cells, as only a fraction of target cells express the antigen recognized by chimeric antigen receptors (CAR-T), limiting their efficacy.
Development of fusion proteins comprising a chemokine and a constitutively active immune sensor signaling pathway protein, which are expressed in immune cells and trigger robust type I interferon secretion upon recognition of target cells, inducing a paracrine immune response against adjacent cancer cells.
The fusion proteins achieve enhanced cancer cell targeting by activating a strong and rapid type I interferon response, effectively eradicating cancer cells even when not all cells express the target antigen, through local interferon production and immune system recruitment.
Smart Images

Figure IL2026050388_12112026_PF_FP_ABST
Abstract
Description
CHIMERIC IMMUNE ACTIVATION PROTEINS AND USE THEREOFCROSS REFERENCE TO REEATED APPLICATIONS
[0001] This application claims the benefit of priority of U.S. Provisional Patent Application No. 63 / 801,867, filed May 8, 2025, the contents of which are all incorporated herein by reference in their entirety.REFERENCE TO AN ELECTRONIC SEQUENCE LISTING
[0002] The contents of the electronic sequence listing (EDIT-P-006-PCT.xml; Size: 324,304 bytes; and Date of Creation: May 4, 2026) is herein incorporated by reference in its entirety.FIELD OF INVENTION
[0003] The present invention is in the field of cancer therapeutics.BACKGROUND OF THE INVENTION
[0004] Immune sensor signaling pathway proteins are a group of diverse proteins, including pattern recognition receptors and associated signaling pathway molecules, that sense cytoplasmic DNA / RNA and trigger the production of type 1 interferon as a response. These signaling pathways protect against bacterial and viral infection as the interferon acts to enhance immune activity against the virus infected cell and its neighbors. The various immune sensor proteins work through interferon transcriptional regulators such as Stimulator of Interferon Genes (STING) and Mitochondrial antiviral-signaling protein (MAVS). These regulators activate interferon regulatory factors such as IRF3 and to a lesser extent IRF7. This leads to the secretion of type I interferon. Improved artificial proteins of the immune sensor signaling pathway that can activate the immune system via the innate type I interferon pathway, especially against cancer, are greatly needed.SUMMARY OF THE INVENTION
[0005] The present invention provides fusion proteins comprising a single polypeptide chain comprising a chemokine and a constitutively active protein of the immune sensor signalingpathway. Nucleic acid molecules encoding the fusion proteins of the invention are also provided. Immune cells comprising a fusion protein of the invention or nucleic acid molecule of the invention are also provided, as are pharmaceutical compositions comprising same. Methods of treating cancer comprising administering the fusion protein, nucleic acid molecule, immune cell or pharmaceutical composition of the invention are also provided. Constitutively active immune sensor proteins of the invention are also provided.
[0006] According to a first aspect, there is provided a fusion protein comprising a single polypeptide chain comprising a chemokine and a constitutively active protein of the immune sensor signaling pathway.
[0007] According to some embodiments, the chemokine is selected from Chemokine (C-C motif) ligand 1 (CCL1), CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CXCL3, CCL9, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL2 and variants thereof.
[0008] According to some embodiments, the chemokine is selected from CCL5, CCL4, CCL3 and variants thereof.
[0009] According to some embodiments, the CCL5 comprises SEQ ID NO: 5 or a sequence with at least 85% sequence identity thereto, the CCL4 comprises SEQ ID NO: 4 or a sequence with at least 85% sequence identity thereto, the CCL3 comprises SEQ ID NO: 3 or a sequence with at least 85% sequence identity thereto or a combination thereof.
[0010] According to some embodiments, a variant targets the fusion protein to a non-lytic vesicle in a T cell and produces secretion of the fusion protein upon activation of the T cell.[Oil] According to some embodiments, the variant of CCL5 is a variant with reduced binding to heparin and comprises a sequence selected from SEQ ID NO: 45 and 49-64.
[0012] According to some embodiments, the variant is a variant of SEQ ID NO: 5 and comprises a sequence selected from SEQ ID NO: 106-121.
[0013] According to some embodiments, the variant is a variant of SEQ ID NO: 4 and comprises a sequence selected from SEQ ID NO: 138-142.
[0014] According to some embodiments, the variant is a variant of SEQ ID NO: 3 and comprises a sequence selected from SEQ ID NO: 149-150.
[0015] According to some embodiments, the protein of the immune sensor signaling pathway is selected from: cGAS, MAVS, IRF3, IRF7, MDA5, STING, RIGI, IFN-B and fragments and variants thereof.
[0016] According to some embodiments, the constitutively active protein of the immune sensor signaling pathway is selected from those provided in Table 2.
[0017] According to some embodiments, the constitutively active protein of the immune sensor signaling pathway is a fragment of Mitochondrial antiviral-signaling protein (MAVS) comprising a CARD domain.
[0018] According to some embodiments, the constitutively active immune sensor signaling pathway protein comprises or consists of SEQ ID NO: 29 or a variant thereof that increases MAVS signaling.
[0019] According to some embodiments, the variant comprises SEQ ID NO: 30 or SEQ ID NO: 154.
[0020] According to some embodiments, the constitutively active protein of the immune sensor signaling pathway is a truncation of cyclic GMP-AMP [cGAMP] synthase (cGAS) lacking its N-terminal domain.
[0021] According to some embodiments, the immune sensor signaling pathway protein comprises or consists of SEQ ID NO: 46.
[0022] According to some embodiments, the constitutively active protein of the immune sensor signaling pathway is interferon beta (IFNb).
[0023] According to some embodiments, the immune sensor signaling pathway protein comprises or consists of SEQ ID NO: 162.
[0024] According to some embodiments, the fusion protein comprises an amino acid linker between the chemokine and constitutively active protein of the immune sensor signaling pathway.
[0025] According to some embodiments, the chemokine comprises or consists of an amino acid sequence selected from SEQ ID NO: 3-5, 106-121, 138-142 and 149-150 and the constitutively active immune sensor protein comprising or consisting of an amino acid sequence selected from SEQ ID NO: 30 and 154.
[0026] According to some embodiments, a sequence of the fusion protein comprises or consists of an amino acid sequence selected from SEQ ID NO: 37, 122-137, 143-148, 151-153 and 155-159.
[0027] According to some embodiments, the fusion protein comprises or consists of SEQ ID NO: 65.
[0028] According to some embodiments, the fusion protein comprises or consists of SEQ ID NO: 163.
[0029] According to another aspect, there is provided a nucleic acid molecule encoding a fusion protein of the invention.
[0030] According to some embodiments, the nucleic acid molecule comprises a promoter operably linked to a first coding sequence encoding the fusion protein of the invention.
[0031] According to some embodiments, the promoter comprises or consists of SEQ ID NO: 66 or 67.
[0032] According to some embodiments, the nucleic acid molecule further comprises a 5’ untranslated region (UTR) between the promoter and the first coding sequence, a 3 ’ UTR 3 ’ to the first coding sequence, or both, optionally wherein the 5 ’ UTR comprises or consists of SEQ ID NO: 68, the 3’ UTR comprises or consists of SEQ ID NO: 69 or both.
[0033] According to some embodiments, the nucleic acid molecule further comprises a second coding sequence encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR).
[0034] According to some embodiments, the second coding sequence encodes a CAR.
[0035] According to some embodiments, the CAR comprises an antigen binding domain that binds to a tumor antigen.
[0036] According to some embodiments, the tumor antigen is selected from Receptor tyrosine-protein kinase erbB-2 (HER2 / ERBB2), claudin 6 (CLDN6) and lymphocyte antigen 6 family member G6D (LY6G6D).
[0037] According to some embodiments, the tumor antigen is HER2 and the CAR comprises the antigen binding domain of trastuzumab.
[0038] According to some embodiments, the nucleic acid molecule comprises between the coding sequence encoding the fusion protein and the second coding sequence encoding the CAR a furin cleavage site or a ribosomal skipping peptide, optionally wherein the ribosomal skipping peptide is selected from a P2A peptide, a T2A peptide, an E2A peptide and an F2A peptide.
[0039] According to some embodiments, the nucleic acid molecule comprises both a furin cleavage site and a T2A peptide between the first coding sequence and the second coding sequence.
[0040] According to another aspect, there is provided an immune cell expressing at least one of:a) a fusion protein of the invention and a CAR;b) a nucleic acid molecule of the invention and a nucleic acid molecule encoding a CAR; andc) a nucleic acid molecule of the invention.
[0041] According to some embodiments, the immune cell is a T cell, a natural killer (NK) cell or a macrophage.
[0042] According to some embodiments, the immune cell is a CD8 T cell or a CD4 T cell.
[0043] According to some embodiments, the immune cell comprises upon forming an immunological synapse secretion of a type I interferon at a level that is at least 10 times higher than secretion by an immune cell that does not express any one of (a), (b) and (c).
[0044] According to some embodiments, the type I interferon is interferon beta (IFNb).
[0045] According to another aspect, there is provided a pharmaceutical composition comprising at least one of:a) a fusion protein of the invention and a CAR;b) a nucleic acid molecule of the invention and a nucleic acid molecule encoding a CAR;c) a nucleic acid molecule of the invention; andd) an immune cell of the invention;and a pharmaceutically acceptable carrier, excipient or adjuvant.
[0046] According to another aspect, there is provided a method of treating a disease treatable by activation of an innate immune response in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of the invention, thereby treating a disease treatable by activation of an innate immune response.
[0047] According to some embodiments, the activation of an innate immune response is activation of a type I interferon response.
[0048] According to some embodiments, the activation of an innate immune response is activation of an innate immune response against a cell expressing a target antigen and wherein the CAR binds the target antigen.
[0049] According to some embodiments, the disease is cancer.
[0050] According to some embodiments, the cancer expresses a surface antigen that is bound by the CAR.
[0051] According to some embodiments, the cancer is a solid cancer, optionally wherein the cancer is selected from breast cancer and ovarian cancer.
[0052] According to another aspect, there is provided a method of designing an immune sensor signaling pathway fusion protein, the method comprising;a) selecting a coding sequence encoding a chemokine selected from CCL3, CCL4 and CCL5;b) selecting a coding sequence encoding a constitutively active protein of the immune sensor signaling pathway protein; andc) linking the selected coding sequence encoding a chemokine to the selected sequence encoding a constitutively active immune sensor protein via a peptide linker to produce a fusion protein;thereby, designing an immune sensor fusion protein.
[0053] According to some embodiments, the linking comprises linking the coding sequence encoding a chemokine is N-terminal to the selected sequence encoding a constitutively active immune sensor protein.
[0054] According to some embodiments, the method further comprises expressing the produced fusion protein in an immune cell and measuring secretion of a type I interferon by the immune cell with and without activation of the immune cell and selecting a produced fusion protein that causes the immune cell to secretes at least 10 times more of the type I interferon when the immune cell is activated as compared to when it is not activated.
[0055] According to another aspect, there is provided a method of generating a cytotoxic immune cell against a target antigen, the method comprising;a) designing an immune sensor fusion protein by a method of the invention; b) selecting a chimeric antigen receptor (CAR) against the target antigen;andc) expressing in a cytotoxic immune cell the designed immune sensor signaling pathway fusion protein and the selected CAR;thereby generating a cytotoxic immune cell against a target antigen.
[0056] According to some embodiments, the method comprises producing a nucleic acid molecule comprising a promoter operably linked to a first open reading frame encoding the immune sensor fusion protein and a second open reading frame encoding the selected CAR and wherein there is a furin cleavage site or a ribosomal skipping peptide between the first open reading frame and the second open reading frame, optionally wherein the ribosomal skipping peptide is selected from a P2A peptide, a T2A peptide, an E2A peptide and an F2A peptide.
[0057] According to some embodiments, both a furin cleavage site and a T2A peptide are between the first open reading frame and the second open reading frame.
[0058] According to another aspect, there is provided a constitutively active immune sensor protein, comprising at least 85% sequence identity to SEQ ID NO: 29 and comprising a mutation at position 77.
[0059] According to some embodiments, the constitutively active immune sensor protein further comprises an N-terminal methionine residue.
[0060] According to some embodiments, the mutation at position 77 is mutation of glycine to lysine, arginine, histidine or glutamine.
[0061] According to some embodiments, the mutation at position 77 is mutation of glycine to lysine (G77K).
[0062] According to some embodiments, the constitutively active immune sensor protein further comprises mutation of valine 81, serine 89 or both.
[0063] According to some embodiments, valine 81 is mutated to lysine, arginine or histidine; serine 89 is mutated to lysine, arginine or histidine; or both.
[0064] According to some embodiments, the constitutively active immune sensor protein comprises mutation of valine 81 to lysine (V8 IK) and mutation of serine 89 to lysine (S89K).
[0065] According to some embodiments, constitutive activity comprises persistent activation of the TBK1-IRF3 pathway, optionally wherein constitutive activity is in the absence of cytoplasmic DNA.
[0066] According to some embodiments, the constitutively active immune sensor protein comprises SEQ ID NO: 154 or a sequence with at least 85% sequence identity thereto.
[0067] According to some embodiments, the constitutively active immune sensor protein comprises SEQ ID NO: 30 or a sequence with at least 85% sequence identity thereto.
[0068] Further embodiments and the full scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.BRIEF DESCRIPTION OF THE DRAWINGS
[0069] Figure 1: Western blot utilizing anti MAVS antibody demonstrates expression in cells expressing either a construct of the invention ( 10_510) or a CAR construct (6 118). A very short 10 second exposure was used due to the very large amount of CCL5+MAVS-CARD mut fusion protein (~23 kDa) produced.
[0070] Figures 2A-B: (2A) A bar graph of interferon beta (IFNb) level in the supernatant of T cells expressing the recited constructs cocultured with HER2 expressing HCC1954 cells compared to T cells expressing the recited constructs when cultured alone. Use of the constitutively active MAVS-CARD3mut fragment (10_510 and 10_511) in the fusion protein with expression of the anti-HER2 CAR produces robust expression. Replacement of MAVS with GFP (0_541 and 0_542) or use of just the CAR (6 118) produces background levels of expression. (2B) A bar graph of relative IFNb levels in supernatant from coculture. Levels are standardized to the amount produced by the MAVS-CARD triple mutant.
[0071] Figure 3: A bar graph of IFNb level in the supernatant of T cells expressing the recited constructs cocultured with HER2 expressing HCC1954 cells compared to T cells expressing the recited constructs when cultured alone. Demonstrated herein are T cells expressing the fusion protein and CAR from the same construct (10_510) or from separate constructs (10_502+6_l 18) when cultured alone or cocultured with HCC1954 cells.
[0072] Figures 4A-B: Bar graphs of IFNb level in the supernatant of T cells expressing the recited constructs cocultured with HER2 expressing HCC1954 cells compared to T cells expressing the recited constructs when cultured alone. Demonstrated herein are T cells expressing the fusion protein of the invention or (4A) a construct lacking CCL5 (10 854) or (4B) lacking the MAVS_CARD3mutant (5 182) when cultured alone or cocultured with HCC1954 cells.
[0073] Figure 5: A bar graph of IFNb level in the supernatant of T cells expressing the recited constructs cocultured with HER2 expressing HCC1954 cells compared to T cells expressing the recited constructs when cultured alone. Demonstrated T cells expressing a fusion protein with active MAVS-CARD triple mut ( 10_510) or with an inactivated MAVS-CARD mut (10 754) when cocultured with HCC1954 or SKOV3 cells.
[0074] Figure 6: A bar graph level in the supernatant of T cells expressing the recited constructs cocultured with HER2 expressing HCC1954 cells compared to T cells expressing the recited constructs when cultured alone. Demonstrated herein are T cells expressing fusion proteins of the invention with WT CCL5 (10 510 and 10 511) or CCL5 mutants with decreased binding to heparin (10 696 and 10 689) when cultured alone or cocultured with HCC1954 cells.
[0075] Figure 7: A bar graph of level in the supernatant of T cells expressing the recited constructs cocultured with HER2 expressing HCC1954 cells compared to T cells expressing the recited constructs when cultured alone. T cells expressing fusion proteins ofthe invention with constitutively active MAVS or mcGAS or IFNb, are shown when cultured alone or cocultured with HCC1954 cells.
[0076] Figures 8A-B: Kaplan Meier survival plots of mice inoculated with 5 million SKOV3 human ovarian carcinoma cells and then treated with (8A) 0.3 million or (8B) 0.5 million CAR-T cells expressing an active immune sensor fusion protein of the invention (IS) or an inactive immune sensor fusion protein. The functional MAVS_CARD3mut or a dead MAVS (E26R) was used. Media was administered as a negative control.
[0077] 9A-C: Bar graphs of IFNb level in the supernatant of T cells expressing the recited constructs cocultured with (9A) CLDN6 expressing OVCAR3 cells, (9B) LY6G6D expressing HT55 cells or (9C) CD 19 expressing NALM6 cells compared to T cells expressing the recited constructs when cultured alone.DETAILED DESCRIPTION OF THE INVENTION
[0078] The present invention, in some embodiments, provides fusion proteins comprising a single polypeptide chain comprising a chemokine and a constitutively active protein of the immune sensor signaling pathway. Nucleic acid molecules encoding a fusion protein are also provided. Immune cells comprising the fusion protein or nucleic acid molecule are also provided. Pharmaceutical compositions comprising the fusion protein, nucleic acid moleculeor immune cells are also provided. Methods of inducing an immune response and treating cancer are also provided. Constitutively active immune sensor proteins of the invention are also provided.
[0079] The invention is based, at least in part, on the unexpected discovery that when an immune cell, expressing the fusion protein of the invention, recognizes a target cell through its chimeric antigen receptor (CAR), the fusion protein triggers the secretion of interferon and promote s immune system recruitment against the target cell . One of the maj or drawbacks of cancer therapeutics is that only a fraction of the target cells ends up expressing the antigen being targeted by the CAR-T. However, as these immune sensor signaling pathway proteins lead to the local production / expression of interferon, the paracrine effect results in even adjacent cancer cells being targeted by the immune system. Thus, this therapeutic modality has a major advantage over others in which each cancer cell must receive the therapeutic agent in order to eradicate the tumor. Without limiting the scope to any mechanism of action. Further, the fusion protein of the invention was found to be constitutively transcribed and translated and sequestered in vesicle in the cytoplasm. The fusion protein is then released upon immune synapse formation with a cancer cell via the CAR or TCR. This results in a rapid and very strong activation of the type I interferon pathway and produces robust type I interferon levels around the cancer cell. This rapid and strong action is not present when the constitutive protein is regulated on the transcriptional level.
[0080] According to a first aspect, there is provided a fusion protein comprising a chemokine and a protein of the immune sensor signaling pathway.
[0081] As used herein, the term “fusion protein” refers to a single polypeptide chain that includes amino acid sequence from at least two different proteins. It will thus be clear that a fusion protein does not refer to a protein complex of two or more proteins, rather it refers to a single polypeptide comprised of a single amino acid chain. In some embodiments, the fusion protein comprises an amino acid sequence from a first protein and a second protein. In some embodiments, the first protein is a chemokine. In some embodiments, the second protein is a protein of the immune sensor signaling pathway.
[0082] In some embodiments, the fusion protein comprises at least 50, 75, 100, 125, 150, 200, 250, or 300 amino acids. Each possibility represents a separate embodiment of the invention. In some embodiments, the fusion protein comprises at least 150 amino acids. In some embodiments, the fusion protein comprises at least 200 amino acids. In some embodiments, the amino acid sequence from the first protein comprises at least 10, 20, 25,30, 40, 50, 60, 70, 75, 80, 90 or 100 amino acids. Each possibility represents a separate embodiment of the invention. In some embodiments, the amino acid sequence from the first protein consists of at least 10, 20, 25, 30, 40, 50, 60, 70, 75, 80, 90 or 100 amino acids. Each possibility represents a separate embodiment of the invention. In some embodiments, the amino acid sequence from the second protein comprises at least 10, 20, 25, 30, 40, 50, 60, 70, 75, 80, 90 or 100 amino acids. Each possibility represents a separate embodiment of the invention. In some embodiments, the amino acid sequence from the second protein consists of at least 10, 20, 25, 30, 40, 50, 60, 70, 75, 80, 90 or 100 amino acids. Each possibility represents a separate embodiment of the invention. In some embodiments, the fusion protein consists of between 50-250 amino acids. In some embodiments, the fusion protein consists of between 100-250 amino acids. In some embodiments, the fusion protein consists of between 150-250 amino acids. In some embodiments, the fusion protein consists of between 175 and 225 amino acids.
[0083] In some embodiments, the chemokine is the complete chemokine. In some embodiments, the chemokine is a fragment of the chemokine. In some embodiments, the chemokine is a variant of the chemokine. In some embodiments, the chemokine is a mutant of the chemokine. In some embodiments, the chemokine is a truncation of the chemokine. In some embodiments, the chemokine is a chemokine that is sequestered in a vesicle in the cytoplasm of an immune cell until the immune cell forms an immune synapse and then is released from the vesicle. In some embodiments, the variant of the chemokine (e.g., a mutant, truncation, fragment) is still retained in the vesicle and released upon immune synapse formation.
[0084] In some embodiments, the chemokine is selected from the proteins provided in Table 1. In some embodiments, the chemokine is Chemokine (C-C motif) ligand 5 (CCL5). In some embodiments, the chemokine is CCL1. In some embodiments, the chemokine is CCL2. In some embodiments, the chemokine is CCL3. In some embodiments, the chemokine is CCL4. In some embodiments, the chemokine is CCL6. In some embodiments, the chemokine is CCL8. In some embodiments, the chemokine is CXCL3. In some embodiments, the chemokine is CCL9. In some embodiments, the chemokine is CCL11. In some embodiments, the chemokine is CCL12. In some embodiments, the chemokine is CCL13. In some embodiments, the chemokine is CCL14. In some embodiments, the chemokine is CCL15. In some embodiments, the chemokine is CCL16. In some embodiments, the chemokine is CCL17. In some embodiments, the chemokine is CCL18. In some embodiments, the chemokine is CCL19. In some embodiments, the chemokine isCCL20. In some embodiments, the chemokine is CCL21. In some embodiments, the chemokine is CCL22. In some embodiments, the chemokine is CCL23. In some embodiments, the chemokine is CCL24. In some embodiments, the chemokine is CCL25. In some embodiments, the chemokine is CCL26. In some embodiments, the chemokine is CCL27. In some embodiments, the chemokine is CCL28. In some embodiments, the chemokine is a human chemokine. In some embodiments, each of CCL1, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CXCL3, CCL11, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27 and CCL28 is a human protein. In some embodiments, each of CCL6, CCL9 and CCL12 is a mouse protein. In some embodiments, the chemokine comprises a mutation that reduces binding to an interacting protein. In some embodiments, the interacting protein is its receptor. In some embodiments, the interacting protein is heparin.
[0085] In some embodiments, the chemokine comprises a sequence selected from SEQ ID NO: 1-28 or a variant thereof comprising at least 85% sequence identity. In some embodiments, at least 85% is at least 90%. In some embodiments, at least 85% is at least 95%. In some embodiments, at least 85% is at least 97%. In some embodiments, at least 85% is at least 99%. In some embodiments, at least 85% is 100%. In some embodiments, the variant retains being sequestered and released upon immune synapse formation. In some embodiments, the chemokine comprises SEQ ID NO: 5. In some embodiments, the chemokine comprises SEQ ID NO: 5 or a sequence with at least 85% identity thereto. In some embodiments, a variant of SEQ ID NO: 5 comprises SEQ ID NO: 45. In some embodiments, a variant of SEQ ID NO: 5 comprises SEQ ID NO: 49. In some embodiments, a variant of SEQ ID NO: 5 comprises or consists of any one of SEQ ID NO: 49-64. Each possibility represents a separate embodiment of the invention. In some embodiments, a variant of SEQ ID NO: 5 comprises or consists of SEQ ID NO: 50. In some embodiments, a variant of SEQ ID NO: 5 comprises or consists of SEQ ID NO: 51.
[0086] The immune sensor signaling pathway refers to an innate immune nucleic acid sensing and type I interferon signaling pathway. In certain contexts, it encompasses the cytosolic DNA sensor signaling pathway, the cytosolic RNA sensor signaling pathway and the cyclic di-nucleotide signaling pathway. In some embodiments, the immune sensor signaling pathway comprises the cGAS-STING pathway (cyclic GMP-AMP synthase -stimulator of interferon genes) and / or the RIGI-MAVS pathway, and / or the MDA5-MAVS pathway. In some embodiments, the protein of the immune sensor signaling pathway comprises a sensor protein, adaptor protein, signaling mediator, transcription factor,interferon effector molecule, or functional fragment thereof. In some embodiments, the protein of the immune sensor signaling pathway is selected from the ground consisting of: cyclic GMP-AMP synthase (cGAS), Stimulator of interferon genes (STING, STING1, or TMEM 173), retinoic acid-inducible gene I (RIGI / DDX58), melanoma differentiation-associated protein 5 (MDA5 or IFIH1), Mitochondrial antiviral-signaling protein (MAVS), interferon regulatory factor 3 (IRF3), interferon regulatory factor 7 (IRF7), interferon-beta (IFN-P), and any nucleic acid-sensing Toll-like receptor including TLR3, TLR7, TLR8, and TLR9. In some embodiments, the constitutively active protein is selected from any constitutively active forms of: Cyclic GMP-AMP synthase (cGAS) protein, retinoic acidinducible gene I (RIGI or DDX58) protein, melanoma differentiation-associated protein 5 (MDA5 or IFIH1), mitochondrial antiviral signaling protein (MAVS) protein, any combination thereof, or any functional fragment thereof. In some embodiments, the constitutively active protein is not STING.
[0087] In some embodiments, the fusion protein of the instant invention comprises CCL5 bound to immune proteins, in particular cGAS, RIGI, MDA5, MAVS, IRF3, IRF7, STING, IFNB, DncV, DncV2, disA, dacA and WspR or fragments or variants thereof, capable of inducing a strong immune response against those target cells. In some embodiments, the fusion protein of the instant invention comprises CCL4 bound to immune proteins, in particular cGAS, RIGI, MDA5, MAVS, IRF3, IRF7, STING, IFNB, DncV, DncV2, disA, dacA and WspR or fragments or variants thereof, capable of inducing a strong immune response against those target cells. In some embodiments, the fusion protein of the instant invention comprises CCL3 bound to immune proteins, in particular cGAS, RIGI, MDA5, MAVS, IRF3, IRF7, STING, IFNB, DncV, DncV2, disA, dacA and WspR or fragments or variants thereof, capable of inducing a strong immune response against those target cells. cGAS and other cyclic dinucleotide synthases have the added benefit of producing a paracrine effect conferred by secretion of their product, the intermediate dinucleotide signaling molecule, (e.g., cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) for cGAS), to neighboring cells. In some embodiments, the protein of the immune sensor signaling pathway is selected from: cGAS, MAVS, IRF3, IRF7, MDA5, STING, RIGI, IFN-B and fragments and variants thereof. In some embodiments, the protein of the immune sensor signaling pathway is selected from: cGAS, MAVS, IRF3, IRF7, MDA5, STING, RIGI, and IFN-B.
[0088] In some embodiments, the protein of the immune sensor signaling pathway is constitutively active. In some embodiments, constitutively active is inducing constitutivesignaling through the pathway. In some embodiments, constitutively active comprises inducing constitutive activation of the pathway. In some embodiments, activation is activation of an interferon regulatory factor (IRF). In some embodiments, the interferon regulatory factor is selected from IRF3 and IRF7. In some embodiments, the interferon regulatory factor is IRF3. In some embodiments, activation is activation of the interferon type I response. In some embodiments, the response is an immune response. In some embodiments, activation is activation of transcription, translation or both of a type I interferon. Type I interferons comprise both alpha and beta interferons, but also less well studied interferons such as interferon omega, epsilon and kappa. In some embodiments, the type I interferon is interferon alpha. In some embodiments, the type I interferon is interferon beta (IFNB1). Examples include, but are not limited to IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17 and IFNA21, IFNW1, IFNE, IFNK and IFNB1. Any type I interferon’s expression can be measured in order to determine activation of the pathway. According to some embodiments, constitutively active comprises constitutive activation of mitochondrial antiviral signaling protein (MAVS) or Stimulator of interferon genes (STING). According to some embodiments, constitutively comprises in the absence of cytosolic DNA, uncapped RNA or both.
[0089] As used herein, the “constitutively active protein of the immune sensor signaling pathway” refers to a protein of the immune sensor signaling pathway that exerts downstream biological activity in the absence of the natural upstream activating stimulus, including a protein rendered constitutively active by engineering and a protein whose activity is inherent once expressed or present. In some embodiments, the constitutively active protein is selected from any constitutively active form of cyclic GMP-AMP synthase (cGAS), retinoic acidinducible gene I (RIG-I or DDX58), melanoma differentiation-associated protein 5 (MDA5 or IFIH1), mitochondrial antiviral signaling protein (MAVS), stimulator of interferon genes (STING, STING1, or TMEM173), interferon regulatory factor 3 (IRF3), interferon regulatory factor 7 (IRF7), interferon-beta (IFN-J3), any combination thereof, or any functional fragment thereof.
[0090] In some embodiments, the constitutively active protein of the immune sensor signaling pathway is selected from those provided in Table 2. In some embodiments, the constitutively active protein of the immune sensor signaling pathway is selected from SEQ ID NO: 29-34, 154, 162 and 166-171 or a variant thereof comprising at least 85% sequence identity and which constitutively activates the pathway. In some embodiments, theconstitutively active protein of the immune sensor signaling pathway is selected from SEQ ID NO: 29-34, 154 and 162 or a variant thereof comprising at least 85% sequence identity and which constitutively activates the pathway. In some embodiments, at least 85% is at least 90%. In some embodiments, at least 85% is at least 95%. In some embodiments, at least 85% is at least 97%. In some embodiments, at least 85% is at least 99%. In some embodiments, at least 85% is 100%. In some embodiments, the protein provided in Table 2 is SEQ ID NO: 29. In some embodiments, the protein provided in Table 2 is SEQ ID NO: 30. In some embodiments, the protein provided in Table 2 is SEQ ID NO: 31. In some embodiments, the protein provided in Table 2 is SEQ ID NO: 32. In some embodiments, the protein provided in Table 2 is SEQ ID NO: 33. In some embodiments, the protein provided in Table 2 is SEQ ID NO: 34. In some embodiments, the protein provided in Table 2 is SEQ ID NO: 154. In some embodiments, the protein provided in Table 2 is SEQ ID NO: 162. In some embodiments, the constitutively active protein of the immune sensor signaling pathway is SEQ ID NO: 29 or a variant thereof that increases MAVS signaling. In some embodiments, the variant is SEQ ID NO: 30. In some embodiments, the constitutively active protein of the immune sensor signaling pathway is SEQ ID NO: 30. In some embodiments, the variant is SEQ ID NO: 154. In some embodiments, the constitutively active protein of the immune sensor signaling pathway is SEQ ID NO: 154. In some embodiments, the constitutively active protein of the immune sensor signaling pathway is SEQ ID NO: 31. In some embodiments, the constitutively active protein of the immune sensor signaling pathway is SEQ ID NO: 32. In some embodiments, the constitutively active protein of the immune sensor signaling pathway is a truncation of cGAS lacking its N-terminal domain. In some embodiments, the truncation comprises SEQ ID NO: 46. In some embodiments, the truncation comprises SEQ ID NO: 32. In some embodiments, the truncation comprises SEQ ID NO: 34. In some embodiments, a truncation is a fragment. In some embodiments, the constitutively active protein of the immune sensor signaling pathway is SEQ ID NO: 33. In some embodiments, the constitutively active protein of the immune sensor signaling pathway is SEQ ID NO: 162. In some embodiments, the constitutively active protein of the immune sensor signaling pathway is a MDA5 CARD domain. In some embodiments, the MDA5 CAR domain comprises or consists of SEQ ID NO: 167. In some embodiments, the constitutively active protein of the immune sensor signaling pathway is a mutant MDA5. In some embodiments, the MDA5 mutant is SEQ ID NO: 166. In some embodiments, the MDA5 mutant is SEQ ID NO: 168. In some embodiments, the constitutively active protein of the immune sensor signaling pathway is a mutant IRF3. In some embodiments, the IRF3 mutant is SEQ ID NO: 169. In some embodiments, the IRF3 mutant is SEQ ID NO: 170. Insome embodiments, the IRF3 mutant is and IRF7 and IRF3 fusion protein. In some embodiments, the constitutively active protein of the immune sensor signaling pathway is a IRF7 and IRF3 fusion protein. In some embodiments, the fusion protein comprises a mutated IRF3. In some embodiments, the fusion protein comprises SEQ ID NO: 171. In some embodiments, the fusion protein comprises the DNA binding domain (DBD) and constitutive activation domain (CAD) domains from IRF7 and the proline-rich domain (Pro), transactivation domain (TAD) and signal response domain (SRD) domains from IRF3 and wherein the SRD domain comprises the 5D mutation (S397D, S399D, S403D, T405D, and S406D with numbering in IRF3-Uniprot Q14653).
[0091] In some embodiments, a constitutively active MAVS is a mutant MAVS. In some embodiments, the mutant MAVS comprises a single mutation. In some embodiments, a constitutively active MAVS comprises multiple mutations. In some embodiments, a constitutively active MAVS mutant, including full-length MAVS or a fragment composed of the CARD-domain only, promotes spontaneous CARD oligomerization, leading to persistent activation of the TBK1-IRF3 pathway and continuous IFN-a / p production. In some embodiments, the wild-type MAVS CARD domain comprises or consists of SEQ ID NO: 29. In some embodiments, the mutant MAVS CARD domain comprises at least one mutation selected from G77K, V81K and S89K in SEQ ID NO: 29. It will be understood that these mutations correspond to G78K, V82K and S90K in a wild-type MAVS protein, but as the leading methionine has been removed from SEQ ID NO: 29, since it will be part of a fusion protein, each amino acid position is one earlier. In some embodiments, the mutant MAVS CARD domain comprises a G77K mutation in SEQ ID NO: 29. In some embodiments, the mutant MAVS CARD domain comprises at least two mutations selected from G77K, V81K and S89K in SEQ ID NO: 29. In some embodiments, the mutant MAVS CARD domain comprises G77K, V81K and S89K mutations in SEQ ID NO: 29. In some embodiments, the mutant MAVS CARD domain comprises or consists of SEQ ID NO: 30. In some embodiments, the mutant MAVS CARD domain comprises or consists of SEQ ID NO: SEQ ID NO: 154. In some embodiments, the constitutively active protein ofthe immune sensor signaling pathway is selected from SEQ ID NO: 30 and 154 or a variant thereof comprising at least 85% sequence identity and which constitutively activates the pathway. In some embodiments, at least 85% is at least 90%. In some embodiments, at least 85% is at least 95%. In some embodiments, at least 85% is at least 97%. In some embodiments, at least 85% is at least 99%. In some embodiments, at least 85% is 100%. In some embodiments, the variant comprises at least one of lysine at position 77, lysine at position 81 and lysine atposition 89 and retains constitutive activity. In some embodiments, the variant comprises at least two of lysine at position 77, lysine at position 81 and lysine at position 89 and retains constitutive activity. In some embodiments, the variant comprises lysine at position 77, lysine at position 81 and lysine at position 89 and retains constitutive activity.
[0092] Additional constitutively protein of the immune sensor signaling pathway are known in the art. For example, constitutively active MDA5 proteins are disclosed in SEQ ID NO: 166, 167 and 168, and constitutively active IFR3 proteins are disclosed in SEQ ID NO: 169, 170 and 171. In some embodiments, the constitutively protein of the immune sensor signaling pathway is a constitutively active immune sensor protein of the invention. In some embodiments, the constitutively protein of the immune sensor signaling pathway is a variant of the invention.
[0093] By another aspect, there is provided a constitutively active immune sensor protein comprising at least 85% sequence identity to SEQ ID NO: 29 and comprising a mutation at position 77.
[0094] By another aspect, there is provided an isolated variant of a protein comprising the amino acid sequence of SEQ ID NO: 29, wherein the variant comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 29 and which comprises a mutation at position 77.
[0095] By another aspect, there is provided a constitutively active immune sensor protein comprising at least 85% sequence identity to SEQ ID NO: 154 and which comprises a lysine at position 77.
[0096] By another aspect, there is provided an isolated variant of a protein comprising the amino acid sequence of SEQ ID NO: 154, wherein the variant comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 154 and which comprises a lysine at position 77.
[0097] In some embodiments, SEQ ID NO: 29 further comprises an N-terminal methionine (SEQ ID NO: 214). In some embodiments, SEQ ID NO: 154 further comprises an N-terminal methionine (SEQ ID NO: 215). It will be understood that position 77 in SEQ ID NO: 29 is position 78 in SEQ ID NO: 214 and position 77 in SEQ ID NO: 154 is position 78 in SEQ ID NO: 215. Going forward, all position numbering with be given with respect to SEQ ID NO: 29 or 154, but it will be understood that constructs with the N-terminal methionine are also intended and in those proteins the numbering will be one greater and with respect to SEQ ID NOs: 214 and 215. In some embodiments, the mutation at position 77 is mutationof glycine to a positively charged amino acid. In some embodiments, the mutation at position 77 is mutation of glycine to lysine, arginine or histidine. In some embodiments, the mutation at position 77 is mutation of glycine to lysine (G77K). A skilled artisan will appreciate that the data concerning the G77K mutation supports also G77R and G77H mutations as these three amino acids all bear positive charges. In some embodiments, the mutation at position 77 is mutation of glycine to arginine (G77R). Glutamine is a structural mimetic for neutral lysine, thus a skilled artisan will appreciate that a mutation to glutamine will also be effective in producing constitutive activity. In some embodiments, the mutation at position 77 is mutation of glycine to glutamine (G77Q).
[0098] In some embodiments, the constitutively active immune sensor protein comprises a lysine, arginine, histidine or glutamine at position 77. In some embodiments, the variant comprises a lysine, arginine, histidine or glutamine at position 77. In some embodiments, the constitutively active immune sensor protein comprises a lysine at position 77. In some embodiments, the variant comprises a lysine at position 77.
[0099] In some embodiments, at least 85% is at least 85, 90, 92, 95, 97, 99 or 100%. Each possibility represents a separate embodiment of the invention. In some embodiments, at least 85% is at least 95%. In some embodiments, at least 95% is at least 95, 96, 97, 98, 99 or 100%. Each possibility represents a separate embodiment of the invention. In some embodiments, constitutive activity comprises persistent activation of the TBK1-IRF3 pathway. In some embodiments, constitutive activity is in the absence of DNA. In some embodiments, constitutive activity is constitutive immune activation. In some embodiments, constitutive activity is constitutive interferon secretion. In some embodiments, interferon is a type 1 interferon. In some embodiments, interferon is interferon alpha or beta.
[0100] In some embodiments, the constitutively active immune sensor protein further comprises mutation of valine 81. In some embodiments, the constitutively active immune sensor protein further comprises mutation of serine 89. In some embodiments, the constitutively active immune sensor protein further comprises mutation of both valine 81 and serine 89. In some embodiments, the variant further comprises mutation of valine 81. In some embodiments, the variant further comprises mutation of serine 89. In some embodiments, the variant further comprises mutation of both valine 81 and serine 89.
[0101] In some embodiments, the mutation at position 81 is mutation of valine to a positively charged amino acid. In some embodiments, the mutation at position 81 is mutation of valine to lysine, arginine or histidine. In some embodiments, the mutation at position 81 is mutationof valine to lysine (V81K). A skilled artisan will appreciate that the data concerning the V8 IK mutation supports also V81R and V81H mutations as these three amino acids all bear positive charges. In some embodiments, the mutation at position 81 is mutation of valine to arginine (G81R). Glutamine is a structural mimetic for neutral lysine, thus a skilled artisan will appreciate that a mutation to glutamine will also be effective in producing constitutive activity. In some embodiments, the mutation at position 81 is mutation of valine to glutamine (V81Q).
[0102] In some embodiments, the mutation at position 89 is mutation of serine to a positively charged amino acid. In some embodiments, the mutation at position 89 is mutation of serine to lysine, arginine or histidine. In some embodiments, the mutation at position 89 is mutation of serine to lysine (S89K). A skilled artisan will appreciate that the data concerning the S89K mutation supports also S89R and S89H mutations as these three amino acids all bear positive charges. In some embodiments, the mutation at position 89 is mutation of serine to arginine (S89R). Glutamine is a structural mimetic for neutral lysine, thus a skilled artisan will appreciate that a mutation to glutamine will also be effective in producing constitutive activity. In some embodiments, the mutation at position 89 is mutation of serine to glutamine (S89Q).
[0103] In some embodiments, the constitutively active immune sensor protein comprises a G77K, V81K and S89K triple mutation. In some embodiments, the variant comprises a lysine at position 77, 81 and 89. In some embodiments, the constitutively active immune sensor protein comprises at least 85% sequence identity to SEQ ID NO: 154. In some embodiments, the variant is at least 95% identical to SEQ ID NO: 154. In some embodiments, the constitutively active immune sensor protein comprises at least 85% sequence identity to SEQ ID NO: 30. In some embodiments, the variant is at least 95% identical to SEQ ID NO: 30. In some embodiments, the constitutively active immune sensor protein comprises SEQ ID NO: 154. In some embodiments, the constitutively active immune sensor protein consists of SEQ ID NO: 154. In some embodiments, the constitutively active immune sensor protein comprises SEQ ID NO: 30. In some embodiments, the constitutively active immune sensor protein consists of SEQ ID NO: 30. In some embodiments, the variant comprises SEQ ID NO: 154. In some embodiments, the variant consists of SEQ ID NO: 154. In some embodiments, the variant comprises SEQ ID NO: 30. In some embodiments, the variant consists of SEQ ID NO: 30.
[0104] In some embodiments, the fusion protein is of CCL5 or a variant or fragment thereof and a constitutively active immunosensor protein that is coupled to a signaling cascade thatenhances type I interferon response or a variant or fragment thereof. In some embodiments, the fusion protein is of CCL4 or a variant or fragment thereof and a constitutively active immunosensor protein that is coupled to a signaling cascade that enhances type I interferon response or a variant or fragment thereof. In some embodiments, the fusion protein is of CCL3 or a variant or fragment thereof and a constitutively active immunosensor protein that is coupled to a signaling cascade that enhances type I interferon response or a variant or fragment thereof.
[0105] According to a further aspect there is provided an engineered immune cell possessing chimeric antigen receptor (CAR) recognition, and expressing the fusion protein, wherein upon recognition of the CAR or TCR with a target cell, the fusion protein mediates a Type I interferon immune response and thereby induces recruitment of the immune system against the target cell.
[0106] According to a further aspect there is provided a method of enhancing a type I interferon immune response against target cells, comprising: a) providing a population of engineered immune cells expressing a chimeric antigen receptor (CAR) and a fusion protein comprising CCL5 and an immunosensor; b) exposing the engineered cells to target cells expressing a CAR-recognized antigen; c) activating the fusion protein upon CAR or TCR recognition of the target cell; and d) inducing type I interferons response and recruitment of the immune system against the target cells.
[0107] According to a further aspect there is provided a method of enhancing a type I interferon immune response against target cells, comprising: a) providing a population of engineered immune cells expressing a chimeric antigen receptor (CAR) and a fusion protein comprising CCL4 and an immunosensor; b) exposing the engineered cells to target cells expressing a CAR-recognized antigen; c) activating the fusion protein upon CAR or TCR recognition of the target cell; and d) inducing type I interferons response and recruitment of the immune system against the target cells.
[0108] According to a further aspect there is provided a method of enhancing a type I interferon immune response against target cells, comprising: a) providing a population of engineered immune cells expressing a chimeric antigen receptor (CAR) and a fusion protein comprising CCL3 and an immunosensor; b) exposing the engineered cells to target cells expressing a CAR-recognized antigen; c) activating the fusion protein upon CAR or TCR recognition of the target cell; and d) inducing type I interferons response and recruitment of the immune system against the target cells.
[0109] In some embodiments, these fusion proteins are used for antiviral therapies, treating inflammatory and autoimmune conditions or cancer immunotherapy, leveraging Type I IFN signaling to enhance immune responses. In some embodiments, the fusion protein is for use in treating cancer. In some embodiments, the fusion protein is for use in treating an infection. In some embodiments, the infection is a viral infection. In some embodiments, the infection is a bacterial infection. In some embodiments, the Type I IFN response involves autocrine and paracrine signaling, where IFN-a / p binds to IFNAR1 / IFNAR2, activating the JAK-STAT pathway and inducing the expression of antiviral components, such as PKR, OAS, and ISG15.
[0110] In some embodiments, a constitutively active protein induces a Type I interferon (IFN-ot / p) response through ligand-independent activation of downstream signaling pathways. The constitutively active immune sensor may be derived from pattern recognition receptors (PRRs), such as RIG-I, MDA5, MAVS, STING, cGAS, or TLRs, and engineered to sustain antiviral and inflammatory signaling. In some embodiments, protein of the immune sensor signaling pathway is a PRR.
[0111] In some embodiments, the fusion protein comprises an amino acid linker. In some embodiments, the linker links to the chemokine to the protein of the immune sensor protein signaling pathway. In some embodiments, the amino acid linker comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, 25 or 30 amino acids. Each possibility represents a separate embodiment of the invention. In some embodiments, the amino acid linker comprises at most 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 75, 80, 90 or 100 amino acids. Each possibility represents a separate embodiment of the invention. In some embodiments, the linker is a flexible linker. In some embodiments, the linker is a GS linker. In some embodiments, a GS linker comprises GGGS (SEQ ID NO 164) repeats. In some embodiments, a GS linker comprises GS repeats. In some embodiments, a GS linker comprises GGGGS (SEQ ID NO 165) repeats. In some embodiments, repeats is 1-5 repeats. In some embodiments, the linker is a GGGGS (SEQ ID NO 165) linker. In some embodiments, the linker comprises or consists of SGAGLPLFAARPGANS (SEQ ID NO: 36).
[0112] In some embodiments, the fusion protein comprises SEQ ID NO: 37. In some embodiments, the fusion protein consists of SEQ ID NO: 37. In some embodiments, the fusion protein comprises SEQ ID NO: 65. In some embodiments, the fusion protein consists of SEQ ID NO: 65. In some embodiments, the fusion protein comprises SEQ ID NO: 70. In some embodiments, the fusion protein consists of SEQ ID NO: 70. In some embodiments,the fusion protein comprises SEQ ID NO: 163. In some embodiments, the fusion protein consists of SEQ ID NO: 163.Nucleic acid molecule
[0113] By another aspect, there is provided a nucleic acid molecule encoding a fusion protein of the invention.
[0114] The term "nucleic acid" is well known in the art. A "nucleic acid" as used herein will generally refer to a molecule (i.e., a strand) of DNA, RNA or a derivative or analog thereof, comprising a nucleobase. A nucleobase includes, for example, a naturally occurring purine or pyrimidine base found in DNA (e.g., an adenine "A," a guanine "G," a thymine "T" or a cytosine "C") or RNA (e.g., an A, a G, an uracil "U" or a C).
[0115] The terms “nucleic acid molecule” include but not limited to singlestranded RNA (ssRNA), double-stranded RNA (dsRNA), single-stranded DNA (ssDNA), double-stranded DNA (dsDNA), small RNA such as miRNA, siRNA and other short interfering nucleic acids, snoRNAs, snRNAs, tRNA, piRNA, tnRNA, small rRNA, hnRNA, circulating nucleic acids, fragments of genomic DNA or RNA, degraded nucleic acids, ribozymes, viral RNA or DNA, nucleic acids of infectios origin, amplification products, modified nucleic acids, plasmidical or organellar nucleic acids and artificial nucleic acids such as oligonucleotides.
[0116] In some embodiments, the nucleic acid molecule is DNA. In some embodiments, the nucleic acid molecule is a plasmid. In some embodiments, the nucleic acid molecule is vector. In some embodiments, a vector is an expression vector.
[0117] In some embodiments, the nucleic acid molecule is RNA. In some embodiments, the nucleic acid molecule is mRNA. In some embodiments, such nucleic acid molecule is delivered as naked RNA, LNP, virus, or lentiVirus.
[0118] A vector nucleic acid sequence generally contains at least an origin of replication for propagation in a cell and optionally additional elements, such as a heterologous polynucleotide sequence, expression control element (e.g., a promoter, enhancer), selectable marker (e.g., antibiotic resistance), poly-Adenine sequence.
[0119] The vector may be a DNA plasmid delivered via non-viral methods or via viral methods. The viral vector may be a lentiviral vector, retroviral vector, a herpesviral vector, an adenoviral vector, an adeno-associated viral vector or a poxviral vector. The promoters may be active in mammalian cells. The promoters may be a viral promoter.
[0120] In some embodiments, an open reading frame (or coding region) encoding the fusion protein is operably linked to a promoter. The term “operably linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory element or elements in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription / translation system or in a host cell when the vector is introduced into the host cell).
[0121] In some embodiments, the vector is introduced into the cell by standard methods including electroporation (e.g., as described in From et al., Proc. Natl. Acad. Sci. USA 82, 5824 (1985)), Heat shock, infection by viral vectors, high velocity ballistic penetration by small particles with the nucleic acid either within the matrix of small beads or particles, or on the surface (Klein et al., Nature 327. 70-73 (1987)), and / or the like.
[0122] The term "promoter" as used herein refers to a group of transcriptional control modules that are clustered around the initiation site for an RNA polymerase i.e., RNA polymerase II. Promoters are composed of discrete functional modules, each consisting of approximately 7-20 bp of DNA, and containing one or more recognition sites for transcriptional activator or repressor proteins.
[0123] In some embodiments, nucleic acid sequences are transcribed by RNA polymerase II (RNAP II and Pol II). RNAP II is an enzyme found in eukaryotic cells. It catalyzes the transcription of DNA to synthesize precursors of mRNA and most snRNA and microRNA.
[0124] In some embodiments, mammalian expression vectors include, but are not limited to, pcDNA3, pcDNA3.1 (±), pGL3, pZeoSV2(±), pSecTag2, pDisplay, pEF / myc / cyto, pCMV / myc / cyto, pCR3.1, pSinRep5, DH26S, DHBB, pNMTl, pNMT41, pNMT81, which are available from Invitrogen, pCI which is available from Promega, pMbac, pPbac, pBK-RSV and pBK-CMV which are available from Strategene, pTRES which is available from Clontech, and their derivatives.
[0125] In some embodiments, expression vectors containing regulatory elements from eukaryotic viruses such as retroviruses are used by the present invention. SV40 vectors include pSVT7 and pMT2. In some embodiments, vectors derived from bovine papilloma virus include pBV-lMTHA, and vectors derived from Epstein Bar virus include pHEBO, and p2O5. Other exemplary vectors include pMSG, pAV009 / A+, pMTO10 / A+, pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins under the direction of the SV-40 early promoter, SV-40 later promoter, metallothionein promoter,murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown effective for expression in eukaryotic cells.
[0126] In some embodiments, recombinant viral vectors, which offer advantages such as lateral infection and targeting specificity, are used for in vivo expression. In one embodiment, lateral infection is inherent in the life cycle of, for example, retrovirus and is the process by which a single infected cell produces many progeny virions that bud off and infect neighboring cells. In one embodiment, the result is that a large area becomes rapidly infected, most of which was not initially infected by the original viral particles. In one embodiment, viral vectors are produced that are unable to spread laterally. In one embodiment, this characteristic can be useful if the desired purpose is to introduce a specified gene into only a localized number of targeted cells.
[0127] Various methods can be used to introduce the expression vector of the present invention into cells. Such methods are generally described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Laboratory, New York (1989, 1992), in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Md. (1989), Chang et al., Somatic Gene Therapy, CRC Press, Ann Arbor, Mich. (1995), Vega et al., Gene Targeting, CRC Press, Ann Arbor Mich. (1995), Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Butterworths, Boston Mass. (1988) and Gilboa et at. [Biotechniques 4 (6): 504-512, 1986] and include, for example, stable or transient transfection, lipofection, electroporation and infection with recombinant viral vectors. In addition, see U.S. Pat. Nos. 5,464,764 and 5,487,992 for positive-negative selection methods.
[0128] It will be appreciated that other than containing the necessary elements for the transcription and translation of the inserted coding sequence (encoding the polypeptide), the expression construct of the present invention can also include sequences engineered to optimize stability, production, purification, yield or activity of the expressed polypeptide.
[0129] A person with skill in the art will appreciate that the fusion protein can also be expressed from a nucleic acid construct administered to the individual employing any suitable mode of administration, described hereinabove (i.e., in vivo gene therapy). In one embodiment, the nucleic acid construct is introduced into a suitable cell via an appropriate gene delivery vehicle / method (transfection, transduction, homologous recombination, etc.) and an expression system as needed and then the modified cells are expanded in culture and returned to the individual (i.e., ex vivo gene therapy).
[0130] In some embodiments, the nucleic acid molecule comprises a promoter operably linked to a first coding sequence encoding a fusion protein of the invention. In some embodiments, the promoter is a constitutively active promoter. In some embodiments, the promoter is active in an immune cell. In some embodiments, the promoter is a minimal promoter. In some embodiments the promoter comprises or consists of SEQ ID NO: 66. In some embodiments the promoter comprises or consists of NO: 67.
[0131] In some embodiments, the nucleic acid molecule further comprises a 5’ untranslated region (UTR). In some embodiments, the 5’ UTR is between the promoter and the first coding sequence. In some embodiments, the nucleic acid molecule further comprises a 3’ UTR. In some embodiments, the 3’ UTR is 3’ to the first coding sequence. In some embodiments, the 3’ UTR is 3’ to the first and second coding sequences. In some embodiments, the 5’ UTR comprises or consists of SEQ ID NO: 68. In some embodiments, the 3’ UTR comprises or consists of SEQ ID NO: 69.
[0132] In some embodiments, the nucleic acid molecule further comprises a second coding region encoding a chimeric antigen receptor (CAR). In some embodiments, the nucleic acid molecule further comprises a second coding region encoding a T cell receptor (TCR). In some embodiments, the TCR is an engineered TCR. In some embodiments, the TCR is an artificial TCR. In some embodiments, expression of the CAR or TCR in a T cell or NK cell produces a CAR-T or CAR-NK cell, respectively.
[0133] As used herein, the terms "CAR-T cell” and “CAR-NK cell” refer to an engineered receptor which has specificity for at least one protein of interest (for example a tumor associated antigen) and is grafted onto an immune effector cell (a T cell or NK cell). In some embodiments, the CAR-T cell has the specificity of a monoclonal antibody grafted onto a T-cell. In some embodiments, the CAR-NK cell has the specificity of a monoclonal antibody grafted onto a NK-cell. In some embodiments, the T cell is selected from a cytotoxic T lymphocyte and a regulatory T cell.
[0134] CAR-T and CAR-NK cells and their vectors are well known in the art. Such cells target and are cytotoxic to cells expressing the protein for which the receptor binds. In some embodiments, a CAR-T or CAR-NK cell targets at least one tumor associated protein. In some embodiments, a tumor associated protein is a tumor associated antigen. In some embodiments, the tumor associated protein has increased expression on a cancerous cell as compared to a non-cancerous cell. In some embodiments, the non-cancerous cell is of the same tissue or cell type as the cancerous cell.
[0135] Construction of CAR-T cells is well known in the art. In one non-limiting example, a monoclonal antibody to a viral protein can be made and then a vector coding for the antibody will be constructed. The vector will also comprise a costimulatory signal region. In some embodiments, the costimulatory signal region comprises the intracellular domain of a known T cell or NK cell stimulatory molecule. In some embodiments, the intracellular domain is selected from at least one of the following: CD3Z, CD27, CD28, 4-1BB, 0X40, CD30, CD40, PD- 1, ICOS, lymphocyte function-associated antigen- 1 (LFA- 1), CD2, CD 7, LIGHT, NKG2C, B7- H3, and a ligand that specifically binds with CD83. In some embodiments, the vector also comprises a CD3Z signaling domain. This vector is then transfect, for example by lentiviral infection, into a T-cell. In some embodiments, the CAR is a first generation CAR. In some embodiments, the CAR is a second generation CAR. In some embodiments, the CAR is a third generation CAR. In some embodiments, the CAR is a combination of CARs. In some embodiments, the CAR is a plurality of CARs. In some embodiments, the TCR is a combination of TCRs. In some embodiments, the TCR is a plurality of TCRs. In some embodiments, the CAR is a TGF[3 responsive CAR. In some embodiments, the CAR is a TGFJ3-CAR.
[0136] In some embodiments, the CAR or TCR comprises an antigen binding domain that binds to a cancer antigen. In some embodiments, the antigen is expressed by a target antigen. CARs and their targets are well known in the art and the skilled artisan can select the CAR that is specific to an antigen that is known to be expressed by the cancer to be treated. In some embodiments, the cancer antigen is a tumor antigen. In some embodiments, the cancer antigen is Receptor tyrosine-protein kinase erbB-2 (HER2 / ERBB2). In some embodiments, the CAR comprises the antigen binding domain of the anti-HER2 antibody trastuzumab. In some embodiments, the CAR comprises the amino acid sequence of SEQ ID NO: 35. In some embodiments, the CAR consists of the amino acid sequence of SEQ ID NO: 35. In some embodiments, the cancer antigen is claudin 6 (CLDN6). In some embodiments, the cancer antigen is lymphocyte antigen 6 family member G6D (LY6G6D). In some embodiments, the cancer antigen is CD 19. In some embodiments, the CAR is an anti-CD19 CAR. In some embodiments, the anti-CD19 CAR comprises or consists of SEQ ID NO: 67.
[0137] In some embodiments, the nucleic acid molecule comprises a sequence encoding a protease cleavage site between the first coding sequence and the second coding sequence. In some embodiments, the protease is fiirin. In some embodiments, the fiirin cleavage site comprises or consists of X-Arg-X-Lys / Arg-Arg-X. Another way of stating this is XBXBBX, where B is a basic amino acid and X is a hydrophobic amino acid. In some embodiments,the furin cleavage site comprises or consists of RAKRS (SEQ ID NO: 71). In some embodiments, the furin cleavage site is proceeded by a spacer amino acid sequence. In some embodiments, the spacer amino acid sequence is GSG. In some embodiments, the GSG spacer is encoded by ggctctggc. In some embodiments, the nucleic acid molecule comprises a sequence encoding the spacer amino acid and furin cleavage site between the first coding sequence and the second coding sequence.
[0138] In some embodiments, the nucleic acid molecule comprises a sequence encoding a ribosome skipping peptide between the first coding sequence and the second coding sequence. In some embodiments, a ribosome skipping peptide is a 2A ribosome skipping peptide. In some embodiments, a ribosome skipping peptide is a 2A self-cleaving peptide. In some embodiments, the ribosome skipping peptide induces failure to make a peptide bond between an amino acid and the next amino acid to be produced by the open reading frame thus resulting in two separate proteins being produced. As used herein, a “2A self-cleaving peptide” is the same as a “2A ribosomal skipping peptide”. In some embodiments, the 2A peptide comprises the motif DX1EX2NPGP (SEQ ID NO: 72) wherein XI is any amino acid and X2 is any amino acid. In some embodiments, SEQ ID NO: 72 is DVEXNPGP (SEQ ID NO: 73), wherein X is E or S. In some embodiments, the 2A peptide is selected from a T2A peptide, a P2A peptide, an E2A peptide and an F2A peptide. In some embodiments, the 2A peptide is proceeded by an amino acid spacer. In some embodiments, the amino acid spacer is GSG. In some embodiments, the GSG spacer is encoded by ggctctggc.
[0139] In some embodiments, the 2A peptide is a P2A peptide. In some embodiments, the linker comprises a P2A peptide. In some embodiments, the linker consists of a P2A peptide. In some embodiments, the ribosomal skipping peptide comprises a P2A peptide. In some embodiments, the ribosomal skipping peptide consists of a P2A peptide. In some embodiments, the P2A peptide comprises the amino acid sequence ATNFSLLKQAGDVEENPGP (SEQ ID NO: 75). In some embodiments, the P2A peptide consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the linker comprises or consists of SEQ ID NO: 75. In some embodiments, the ribosomal skipping peptide comprises or consists of SEQ ID NO: 75.
[0140] In some embodiments, the 2A peptide is a T2A peptide. In some embodiments, the linker comprises a T2A peptide. In some embodiments, the linker consists of a T2A peptide. In some embodiments, the ribosomal skipping peptide comprises a T2A peptide. In some embodiments, the ribosomal skipping peptide consists of a T2A peptide. In some embodiments, the T2A peptide comprises the amino acid sequenceEGRGSLLTCGDVEENPGP (SEQ ID NO: 76). In some embodiments, the T2A peptide consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the linker comprises or consists of SEQ ID NO: 76. In some embodiments, the ribosomal skipping peptide comprises or consists of SEQ ID NO: 76. In some embodiments, the T2A peptide comprises the amino acid sequence GSGEGRGSLLTCGDVEENPGP (SEQ ID NO: 216). In some embodiments, the T2A peptide consists of the amino acid sequence of SEQ ID NO: 216. In some embodiments, the linker comprises or consists of SEQ ID NO: 216. In some embodiments, the ribosomal skipping peptide comprises or consists of SEQ ID NO: 216. In some embodiments, the T2A peptide is encoded by the sequence gagggcagaggcagcttgcttacatgtggcgatgtggaggagaaccccgggccc (SEQ ID NO: 74). In some embodiments, the linker is encoded by a sequence comprising SEQ ID NO: 74. In some embodiments, the linker is encoded by a sequence consisting of SEQ ID NO: 74. In some embodiments, the ribosomal skipping peptide is encoded by a sequence comprising SEQ ID NO: 74. In some embodiments, the ribosomal skipping peptide is encoded by a sequence consisting of SEQ ID NO: 74. In some embodiments, the T2A peptide is encoded by the sequence ggctctggcgagggcagaggcagcttgcttacatgtggcgatgtggaggagaaccccgggccc (SEQ ID NO: 217). In some embodiments, the linker is encoded by a sequence comprising SEQ ID NO: 217. In some embodiments, the linker is encoded by a sequence consisting of SEQ ID NO: 217. In some embodiments, the ribosomal skipping peptide is encoded by a sequence comprising SEQ ID NO: 217. In some embodiments, the ribosomal skipping peptide is encoded by a sequence consisting of SEQ ID NO: 217.
[0141] In some embodiments, the 2A peptide is an E2A peptide. In some embodiments, the linker comprises an E2A peptide. In some embodiments, the linker consists of an E2A peptide. In some embodiments, the ribosomal skipping peptide comprises an E2A peptide. In some embodiments, the ribosomal skipping peptide consists of an E2A peptide. In some embodiments, the E2A peptide comprises the amino acid sequence QCTNYALLKLAGDVESNPGP (SEQ ID NO: 77). In some embodiments, the E2A peptide consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the linker comprises or consists of SEQ ID NO: 77. In some embodiments, the ribosomal skipping peptide comprises or consists of SEQ ID NO: 77.
[0142] In some embodiments, the 2A peptide is an F2A peptide. In some embodiments, the linker comprises an F2A peptide. In some embodiments, the linker consists of an F2A peptide. In some embodiments, the ribosomal skipping peptide comprises an F2A peptide. In some embodiments, the ribosomal skipping peptide consists of an F2A peptide. In someembodiments, the F2A peptide comprises the amino acid sequence VKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 78). In some embodiments, the F2A peptide consists of the amino acid sequence of SEQ ID NO: 78. In some embodiments, the linker comprises or consists of SEQ ID NO: 78. In some embodiments, the ribosomal skipping peptide comprises or consists of SEQ ID NO: 78.
[0143] In some embodiments, the furin cleavage site comprises anN-terminal GSG. In some embodiments, a sequence encoding GSG is directly 5 ’ to the sequence encoding the furin cleavage site. In some embodiments, the linker comprises GSG followed by the furin cleavage site. In some embodiments, the open reading frame comprises a sequence encoding GSG directly 5’ to a sequence encoding the furin cleavage site.
[0144] In some embodiments, the ribosomal skipping peptide comprises an N-terminal GSG. In some embodiments, a sequence encoding GSG is directly 5’ to the sequence encoding the ribosomal skipping peptide. In some embodiments, the linker comprises GSG followed by the ribosomal skipping peptide. In some embodiments, the open reading frame comprises a sequence encoding GSG directly 5’ to a sequence encoding the ribosomal skipping peptide.
[0145] In some embodiments, the nucleic acid molecule comprises or consists of SEQ ID NO: 38. In some embodiments, the nucleic acid molecule comprises or consists of a sequence encoding SEQ ID NO: 39. In some embodiments, the nucleic acid molecule comprises or consists of SEQ ID NO: 40. In some embodiments, the nucleic acid molecule comprises or consists of a sequence encoding SEQ ID NO: 41. In some embodiments, the nucleic acid molecule comprises or consists of SEQ ID NO: 47. In some embodiments, the nucleic acid molecule comprises or consists of a sequence encoding SEQ ID NO: 48.Modified immune cells
[0146] By another aspect, there is provided an immune cell comprising a fusion protein of the invention.
[0147] By another aspect, there is provided an immune cell comprising a fusion protein of the invention and a CAR.
[0148] By another aspect, there is provided an immune cell comprising a nucleic acid molecule of the invention.
[0149] By another aspect, there is provided an immune cell comprising a nucleic acid molecule of the invention and a nucleic acid molecule encoding a CAR.
[0150] By another aspect, there is provided a modified chimeric antigen receptor (CAR) T cells that further include the fusion protein, wherein the fusion protein functions as an immune sensor responsible for potentiating type I interferon immune response upon recognition of target cells by the CAR.
[0151] In one embodiment, a modified CAR-T cell comprises a CAR construct targeting a specific antigen on diseased or malignant cells, wherein the CAR-T cell is further engineered to express the fusion protein. In one embodiment, the modified CAR-T cell is genetically engineered.
[0152] In a further embodiment, the modified CAR-T cells are engineered to generate activation of the fusion protein and / or effector molecule (e.g., cytokines, small molecule, second messenger (e.g., cGAMP) of the signaling pathway into the tumor microenvironment. In some embodiments, the secretion enhances immune cell recruitment, activation, and cytotoxic function against target cells by acting as an immune sensor that amplifies immune responses.
[0153] In another embodiment, the modified CAR-T cells express the fusion protein in combination with checkpoint inhibitor modifications. For example, CAR-T cells engineered to co-express the fusion protein and modifications targeting PD-1 or CTLA-4 exhibit sustained cytotoxic activity against target cells by preventing immune exhaustion and enhancing tumor clearance.
[0154] The modified CAR-T cells may be generated using a variety of genetic engineering approaches. In one embodiment, a lentiviral vector is utilized to transduce T cells with nucleic acid sequences encoding the CAR construct and the fusion protein, allowing stable genomic integration and long-term expression. In another embodiment, a transposase-mediated gene insertion system, such as Sleeping Beauty or PiggyBac, is employed to achieve stable integration of the CAR construct and the fusion protein without the use of viral vectors, providing a cost-effective and efficient gene transfer strategy.
[0155] In a further embodiment, the CAR construct and the fusion protein are introduced into T cells via in vitro transcribed (IVT) mRNA electroporation, facilitating transient expression. This approach enables rapid CAR-T cell manufacturing with reduced genomic alterations and lower long-term safety risks. Alternatively, genome editing technologies, such as CRISPR / Cas9 or base editors, may be used to precisely insert the fusion protein into a specific genomic locus, such as the T cell receptor alpha constant (TRAC) locus, ensuring controlled expression while minimizing off-target effects.
[0156] In some embodiments, the immune cell is selected from a T cell, a natural killer (NK) cell and a macrophage. In some embodiments, the immune cell is a T cell. In some embodiments, the immune cell is an NK cell. In some embodiments, the immune cell is a cytotoxic immune cell. In some embodiments, the immune cell is a CD8 T cell. In some embodiments, the immune cell is a CD4 T cell.
[0157] In some embodiments, the immune cell, upon formation of an immunological synapse, produces secretion of a type I interferon at a level that is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90 or 100 times greater than the secretion by an immune cell that does not express a fusion protein, nucleic acid molecule of the invention and a CAR. Each possibility represents a separate embodiment of the invention. In some embodiments, the type I interferon is IFNB1.Constructs
[0158] In some embodiments, there is provided a nucleotide sequence encoding the fusion proteins of the invention. In some embodiments, the expression is regulated by an inducible promotor. Non-limiting examples of inducible promoters include NFAT-inducible promoters, which respond to T-cell activation signals; NF-KB-inducible promoters, activated by inflammatory cytokines such as TNF-a and IL-1J3; tetracycline -inducible (Tet-On / Tet-Off) promoters, which allow drug-controlled gene expression; hypoxia-responsive promoters (HRE), activated under low oxygen conditions; heat shock protein promoters (HSP70 or HSP90), induced by cellular stress; tamoxifen-inducible CreER promoters, used for conditional gene activation; small molecule -inducible promoters, such as those responsive to rapamycin, RU486, or ecdysone; IL-2 or IL- 15 -inducible promoters, activated by cytokine signaling in immune cells.
[0159] In some embodiments, an NFAT-inducible promoter is used to ensure gene expression occurs only upon target recognition, thereby restricting expression of therapeutic genes, cytokines, or costimulatory molecules to CAR-T activation events, enhancing specificity and reducing off-target effects. In some embodiments, an NFAT-inducible promoter is incorporated to drive the expression of genes in a T-cell activation-dependent manner. In some embodiments, this system ensures that gene expression is restricted to activated CAR-T cells, reducing off-target effects and improving safety.
[0160] In some embodiments, the nucleotide sequence further encodes additional functional domains to enhance delivery, localization, and activity of the encoded protein.
[0161] In some embodiments, the nucleotide sequence encodes a cell-penetrating peptide (CPP) to facilitate intracellular delivery of the encoded protein. Non-limiting examples of CPPs include TAT, penetratin, arginine-rich peptides, and transportan.
[0162] In some embodiments, the nucleotide sequence encodes a signal peptide, which ensures proper protein localization.
[0163] In some embodiments, the nucleotide sequence encodes a localization signal, such as a nuclear localization signal (NLS), or endoplasmic reticulum (ER) localization signal, to direct the encoded protein to a specific subcellular compartment.
[0164] In some embodiments, the nucleotide sequence encodes a fusion protein, combining a CPP, signal peptide, and functional domain, ensuring efficient delivery, activation, and localization of the therapeutic or engineered protein.
[0165] In some embodiments, the nucleotide sequence further encodes a chimeric antigen receptor (CAR) to facilitate antigen-specific immune cell activation. Non-limiting examples of chimeric antigen receptors (CARs) include CD19-specific CAR, BCMA-specific CAR, CD20-specific CAR, HER2-specific CAR, Claudin 6-specific CAR, Claudin 18.2-specific CAR, mesothelin-specific CAR, EGFRvIII-specific CAR, LY6G6D specific CAR, MUC1-specific CAR, MUC16-specific CAR, FRa specific CAR, EpCAM specific CAR, TAG72 specific CAR, GPC3 -specific CAR, ROR1 -specific CAR, DLL3 specific CAR, EGFRvIII specific CAR, CD70 specific CAR, NKG2D-based CAR, PSMA-specific CAR, FAP-specific CAR, IL-13Ra2-specific CAR, multi-specific CARs, including bispecific or trivalent CARs targeting multiple antigens such as CD19 / CD20, CD19 / CD22, or HER2 / MUC1 to enhance tumor recognition and reduce antigen escape; and switchable CARs, incorporating drug-inducible domains that allow for external regulation of CAR-T activity.
[0166] In some embodiments, a ribosome skipping element, such as P2A, T2A, E2A, F2A or IRES, is positioned between the fusion protein and the chimeric antigen receptor, enabling expression of multiple proteins from a single transcript while ensuring their proper separation.
[0167] In some embodiments, the chimeric antigen receptor is encoded by a different nucleotide sequence, allowing for independent regulation, expression, or incorporation into a separate genetic construct.CCL5, CCL4 and CCL3 variants
[0168] In some embodiments, CCL5 is human CCL5. In some embodiments, CCL5 is a mutant CCL5. In some embodiments, a mutant is a variant. In some embodiments, the CCL5 mutant comprises one or more mutations in the 40s loop and / or 50s loop, altering its interaction with receptors, glycosaminoglycans (GAGs), or oligomerization properties.
[0169] In some embodiments, mutations in the 40s loop modify the binding affinity of CCL5 to CCR1, CCR3, or CCR5, affecting downstream signaling and immune cell recruitment. In certain embodiments, these mutations enhance or reduce receptor activation to modulate inflammatory responses.
[0170] In some embodiments, mutations in the 50s loop disrupt or enhance CCL5 oligomerization, altering its ability to form higher-order aggregates and affecting chemotactic activity. In certain embodiments, these mutations modulate CCL5-GAG (glycosaminoglycan) interactions, impacting localization and bioavailability in tissues.
[0171] In some embodiments, CCL5 mutants with combined 40s and 50s loop mutations exhibit altered chemoattractant activity, receptor signaling bias, or resistance to proteolytic degradation, making them potential candidates for anti-inflammatory or immunomodulatory therapies.
[0172] In some embodiments, CCL5 is human CCL5. In some embodiments, CCL5 is a mutant CCL5. In some embodiments, a mutant is a variant. In some embodiments, the mutant / variant of CCL5 comprises at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 5. Each possibility represents a separate embodiment of the invention. In some embodiments, the mutant / variant of CCL5 comprises at least 85% sequence identity to SEQ ID NO: 5. In some embodiments, the mutant / variant of CCL5 comprises at least 95% sequence identity to SEQ ID NO: 5.
[0173] In some embodiments, the mutant / variant of CCL5 has reduced binding to heparin and comprises or consist of SEQ ID NO: 45. In some embodiments, the mutant / variant of CCL5 has reduced binding to heparin and comprises or consist of SEQ ID NO: 49. In some embodiments, the mutant / variant of CCL5 has reduced binding to heparin and comprises or consist of SEQ ID NO: 50. In some embodiments, the mutant / variant of CCL5 has reduced binding to heparin and comprises or consist of SEQ ID NO: 51. In some embodiments, the mutant / variant of CCL5 has reduced binding to heparin and comprises or consist of SEQ ID NO: 52. In some embodiments, the mutant / variant of CCL5 has reduced binding to heparin and comprises or consist of SEQ ID NO: 53. In some embodiments, the mutant / variant of CCL5 has reduced binding to heparin and comprises or consist of SEQ ID NO: 54. In someembodiments, the mutant / variant of CCL5 has reduced binding to heparin and comprises or consist of SEQ ID NO: 55. In some embodiments, the mutant / variant of CCL5 has reduced binding to heparin and comprises or consist of SEQ ID NO: 56. In some embodiments, the mutant / variant of CCL5 has reduced binding to heparin and comprises or consist of SEQ ID NO: 57. In some embodiments, the mutant / variant of CCL5 has reduced binding to heparin and comprises or consist of SEQ ID NO: 58. In some embodiments, the mutant / variant of CCL5 has reduced binding to heparin and comprises or consist of SEQ ID NO: 59. In some embodiments, the mutant / variant of CCL5 has reduced binding to heparin and comprises or consist of SEQ ID NO: 60. In some embodiments, the mutant / variant of CCL5 has reduced binding to heparin and comprises or consist of SEQ ID NO: 61. In some embodiments, the mutant / variant of CCL5 has reduced binding to heparin and comprises or consist of SEQ ID NO: 62. In some embodiments, the mutant / variant of CCL5 has reduced binding to heparin and comprises or consist of SEQ ID NO: 63. In some embodiments, the mutant / variant of CCL5 has reduced binding to heparin and comprises or consist of SEQ ID NO: 64.
[0174] In some embodiments, the mutant / variant CCL5 comprises a K78A, K79A, R82A triple mutation (called AAWVA in Table 6). In some embodiments, the mutant / variant CCL5 comprises a K78A mutation, a K79A mutation, and a R82A mutation in SEQ ID NO: 5. It will be understood that CCL5 has a 23 amino acid leader / signal peptide and so in constructs without this leader / signal peptide the numbering will be reduced by 23 (i.e., K55A, K56A, R59A). In some embodiments, the mutant / variant CCL5 amino acid sequence comprises SEQ ID NO: 106. In some embodiments, the mutant / variant CCL5 consists of SEQ ID NO: 106. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 106, which bears an alanine at position 78, an alanine at position 79, and an alanine at position 82 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0175] In some embodiments, the mutant / variant CCL5 comprises a D29A mutation (called D6A in Table 6). In some embodiments, the mutant / variant CCL5 comprises a D29A mutation in SEQ ID NO: 5. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises SEQ ID NO: 107. In some embodiments, the mutant / variant CCL5 consists of SEQ ID NO: 107. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 107, which bears an alanine at position 29 and whichsequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0176] In some embodiments, the mutant / variant CCL5 comprises a S27A mutation (called S4A in Table 6). In some embodiments, the mutant / variant CCL5 comprises a S27A mutation in SEQ ID NO: 5. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises SEQ ID NO: 108. In some embodiments, the mutant / variant CCL5 consists of SEQ ID NO: 108. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 108, which bears an alanine at position 27 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0177] In some embodiments, the mutant / variant CCL5 comprises a S24A and a S27A mutation (called S1A S4A in Table 6). In some embodiments, the mutant / variant CCL5 comprises a S24A and a S27A mutation in SEQ ID NO: 5. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises SEQ ID NO: 109. In some embodiments, the mutant / variant CCL5 consists of SEQ ID NO: 109. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 109, which bears an alanine at position 24 and an alanine at position 27 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0178] In some embodiments, the mutant / variant CCL5 comprises a T30K mutation (called T7K in Table 6). In some embodiments, the mutant / variant CCL5 comprises a T30K mutation in SEQ ID NO: 5. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises SEQ ID NO: 110. In some embodiments, the mutant / variant CCL5 consists of SEQ ID NO: 110. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 110, which bears a lysine at position 30 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0179] In some embodiments, the mutant / variant CCL5 comprises a C33S mutation and a C57S (called C10S_C34S in Table 6). In some embodiments, the mutant / variant CCL5 comprises a C33S mutation and a C57S mutation in SEQ ID NO: 5. In some embodiments,the mutant / variant CCL5 amino acid sequence comprises SEQ ID NO: 111. In some embodiments, the mutant / variant CCL5 consists of SEQ ID NO: 111. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 111, which bears a serine at position 33 and a serine at position 57 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0180] In some embodiments, the mutant / variant CCL5 comprises a K56V mutation (called K33V in Table 6). In some embodiments, the mutant / variant CCL5 comprises a K56V mutation in SEQ ID NO: 5. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises SEQ ID NO: 112. In some embodiments, the mutant / variant CCL5 consists of SEQ ID NO: 112. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 112, which bears a valine at position 56 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0181] In some embodiments, the mutant / variant CCL5 comprises a K56A mutation (called K33A in Table 6). In some embodiments, the mutant / variant CCL5 comprises a K56A mutation in SEQ ID NO: 5. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises SEQ ID NO: 113. In some embodiments, the mutant / variant CCL5 consists of SEQ ID NO: 113. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 113, which bears an alanine at position 56 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0182] In some embodiments, the mutant / variant CCL5 comprises a S24A, S27A, D29A, K56A quadruple mutation (called allA in Table 6). In some embodiments, the mutant / variant CCL5 comprises a S24A mutation, a S27A mutation, a D29A mutation and a K56A mutation in SEQ ID NO: 5. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises SEQ ID NO: 114. In some embodiments, the mutant / variant CCL5 consists of SEQ ID NO: 114. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 114, which bears an alanine at position 24, an alanine at position 27, an alanine at position 29 and an alanine at position 56 and which sequesters thefusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0183] In some embodiments, the mutant / variant CCL5 comprises a F35Y mutation (called F12Y in Table 6). In some embodiments, the mutant / variant CCL5 comprises a F35Y mutation in SEQ ID NO: 5. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises SEQ ID NO: 115. In some embodiments, the mutant / variant CCL5 consists of SEQ ID NO: 115. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 115, which bears an tyrosine at position 35 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0184] In some embodiments, the mutant / variant CCL5 comprises a F35W mutation (called F12W in Table 6). In some embodiments, the mutant / variant CCL5 comprises a F35W mutation in SEQ ID NO: 5. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises SEQ ID NO: 116. In some embodiments, the mutant / variant CCL5 consists of SEQ ID NO: 116. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 116, which bears an tryptophan at position 35 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0185] In some embodiments, the mutant / variant CCL5 comprises a R67A, K68A, R70A triple mutation (called AANA in Table 6). In some embodiments, the mutant / variant CCL5 comprises a R67A mutation, a K68A mutation, and a R70A mutation in SEQ ID NO: 5. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises SEQ ID NO: 117. In some embodiments, the mutant / variant CCL5 consists of SEQ ID NO: 117. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 117, which bears an alanine at position 67, an alanine at position 68, and an alanine at position 70 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0186] In some embodiments, the mutant / variant CCL5 comprises a F35Y, A36V, Y50W, F51W, E89S quintuple mutation (called M5 in Table 6). In some embodiments, the mutant / variant CCL5 comprises a F35Y mutation, an A36V mutation, a Y50W mutation, anF51W mutation and an E89S mutation in SEQ ID NO: 5. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises SEQ ID NO: 118. In some embodiments, the mutant / variant CCL5 consists of SEQ ID NO: 118. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 118, which bears a tyrosine at position 35, a valine at position 36, a tryptophan at position 50, a tryptophan at position 51 and a serine at position 89 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0187] In some embodiments, the mutant / variant CCL5 comprises a deletion from S24 to T31 (called cut8aa in Table 6). In some embodiments, the mutant / variant CCL5 comprises a deletion from S24 to T31 (inclusive of amino acids 24 and 31) in SEQ ID NO: 5. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises SEQ ID NO: 119. In some embodiments, the mutant / variant CCL5 consists of SEQ ID NO: 119. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 119, which does not comprise an insert of S24 to T31 from SEQ ID NO: 5 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 119, which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0188] In some embodiments, the mutant / variant CCL5 comprises a E89S mutation (called E66S in Table 6). In some embodiments, the mutant / variant CCL5 comprises a F35Y mutation in SEQ ID NO: 5. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises SEQ ID NO: 120. In some embodiments, the mutant / variant CCL5 consists of SEQ ID NO: 120. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 120, which bears a serine at position 89 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0189] In some embodiments, the mutant / variant CCL5 comprises a R67A, K68A, R70A, K78A, K79A, R82A sextuple mutation (called AANA_AAWVA in Table 6). In someembodiments, the mutant / variant CCL5 comprises a R67A mutation, a K68A mutation, a R70A mutation, a K78A mutation, a K79A mutation and an R82A mutation in SEQ ID NO: 5. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises SEQ ID NO: 121. In some embodiments, the mutant / variant CCL5 consists of SEQ ID NO: 121. In some embodiments, the mutant / variant CCL5 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 121, which bears an alanine at position 67, an alanine at position 68, an alanine at position 70, an alanine at position 78, an alanine at position 79 and an alanine at position 82 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0190] In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 37. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 37. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 70. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 70. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 122. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 122. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 123. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 123. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 124. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 124. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 125. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 125. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 126. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 126. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 127. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 127. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 128. In someembodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 128. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 129. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 129. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 130. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 130. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 131. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 131. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 132. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 132. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 133. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 133. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 134. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 134. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 135. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 135. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 136. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 136. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 137. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 137. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 158. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 158. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 159. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 159.
[0191] In some embodiments, CCL4 is human CCL4. In some embodiments, CCL4 is a mutant CCL4. In some embodiments, a mutant is a variant.
[0192] In some embodiments, the mutant / variant of CCL4 comprises at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 4. Each possibility represents a separate embodiment of the invention. In some embodiments, the mutant / variant of CCL4 comprises at least 85% sequence identity to SEQ ID NO: 4. In some embodiments, the mutant / variant of CCL4 comprises at least 95% sequence identity to SEQ ID NO: 4.
[0193] In some embodiments, the mutant / variant CCL4 comprises a F36A mutation (called F13A in Table 7). In some embodiments, the mutant / variant CCL4 comprises a F36A mutation in SEQ ID NO: 4. In some embodiments, the mutant / variant CCL4 amino acid sequence comprises SEQ ID NO: 138. In some embodiments, the mutant / variant CCL4 consists of SEQ ID NO: 138. In some embodiments, the mutant / variant CCL4 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 138, which bears an alanine at position 36 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0194] In some embodiments, the mutant / variant CCL4 comprises an A24 to D29 deletion (called cut6aa in Table 7). In some embodiments, the mutant / variant CCL4 comprises a deletion of A24 to D29 (inclusive of amino acids 24 and 29) in SEQ ID NO: 4. In some embodiments, the mutant / variant CCL4 amino acid sequence comprises SEQ ID NO: 139. In some embodiments, the mutant / variant CCL4 consists of SEQ ID NO: 139. In some embodiments, the mutant / variant CCL4 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 139, which does not comprises amino acids A24 to D29 of SEQ IDD NO:4 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention. In some embodiments, the mutant / variant CCL4 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 139, which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0195] In some embodiments, the mutant / variant CCL4 comprises a L57A mutation (called L34A in Table 7). In some embodiments, the mutant / variant CCL4 comprises a F36A mutation in SEQ ID NO: 4. In some embodiments, the mutant / variant CCL4 amino acidsequence comprises SEQ ID NO: 140. In some embodiments, the mutant / variant CCL4 consists of SEQ ID NO: 140. In some embodiments, the mutant / variant CCL4 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 140, which bears an alanine at position 57 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0196] In some embodiments, the mutant / variant CCL4 comprises a S28A, D29A, T32A triple mutation (called allA in Table 7). In some embodiments, the mutant / variant CCL4 comprises a S28A mutation, a D29A mutation and a T32A mutation in SEQ ID NO: 4. In some embodiments, the mutant / variant CCL4 amino acid sequence comprises SEQ ID NO: 141. In some embodiments, the mutant / variant CCL4 consists of SEQ ID NO: 141. In some embodiments, the mutant / variant CCL4 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 141, which bears an alanine at position 28, an alanine at position 29 and an alanine at position 32 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0197] In some embodiments, the mutant / variant CCL4 comprises an E79A, S80A, Q83A triple mutation (called AAWVA in Table 7). In some embodiments, the mutant / variant CCL4 comprises an E79A mutation, a S80A mutation and a Q83A mutation in SEQ ID NO: 4. In some embodiments, the mutant / variant CCL4 amino acid sequence comprises SEQ ID NO: 142. In some embodiments, the mutant / variant CCL4 consists of SEQ ID NO: 142. In some embodiments, the mutant / variant CCL4 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 142, which bears an alanine at position 79, an alanine at position 80 and an alanine at position 83 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0198] In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 143. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 143. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 144. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 144. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 145. In some embodiments, the sequence of the fusion protein consists of the aminoacid sequence provided in SEQ ID NO: 145. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 146. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 146. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 147. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 147. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 148. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 148. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 155. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 155. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 156. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 156.
[0199] In some embodiments, the mutant / variant CCL3 comprises a Q56A mutation (called Q33A in Table 8). In some embodiments, the mutant / variant CCL3 comprises a Q56A mutation in SEQ ID NO: 3. In some embodiments, the mutant / variant CCL3 amino acid sequence comprises SEQ ID NO: 149. In some embodiments, the mutant / variant CCL3 consists of SEQ ID NO: 149. In some embodiments, the mutant / variant CCL3 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 149, which bears an alanine at position 56 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0200] In some embodiments, the mutant / variant CCL3 comprises an E78A, E79A, Q82A triple mutation (called AAWVA in Table 8). In some embodiments, the mutant / variant CCL3 comprises a E78A mutation, a E79A mutation and a Q82A mutation in SEQ ID NO: 3. In some embodiments, the mutant / variant CCL3 amino acid sequence comprises SEQ ID NO: 150. In some embodiments, the mutant / variant CCL3 consists of SEQ ID NO: 150. In some embodiments, the mutant / variant CCL3 amino acid sequence comprises or consists of a sequence with at least 70, 75, 80, 85, 90, 92, 95, 97, or 99% sequence identity to SEQ ID NO: 150, which bears an alanine at position 78, an alanine at position 79 and an alanine at position 82 and which sequesters the fusion protein and releases it upon synapse with a cancer cell. Each possibility represents a separate embodiment of the invention.
[0201] In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 151. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 151. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 152. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 152. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 153. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 153. In some embodiments, the sequence of the fusion protein comprises the amino acid sequence provided in SEQ ID NO: 157. In some embodiments, the sequence of the fusion protein consists of the amino acid sequence provided in SEQ ID NO: 157.Immune sensor proteins
[0202] In some embodiments, the immune sensor protein is an immune sensor protein. In some embodiments, the immune sensor protein is selected from: Cyclic GMP-AMP synthase (cGAS) protein, Retinoic acid-inducible Gene I (RIGI, also known as DDX58) protein, Melanoma Differentiation-Associated protein 5 (MDA5, also known as IFIH1) protein, and a functional fragment or variant thereof. In some embodiments, the immune sensor protein is cGAS. In some embodiments, the immune sensor protein is RIGI. In some embodiments, the immune sensor protein is MDA5. In some embodiments, the immune sensor protein is MAVS.
[0203] In some embodiments, the cyclic dinucleotide synthase is a bacterial cyclic dinucleotide synthase. In some embodiments, the cyclic dinucleotide synthase is selected from cGAS, GMP-AMP synthase DncV (DncV), GMP-AMP synthase DncV2 (DncV2), disA, DacA, WspR and a functional fragment or variant thereof. In some embodiments, the cyclic dinucleotide synthase is DncV. In some embodiments, the bacterial cyclic dinucleotide synthase is a cGAS-like bacterial protein. In some embodiments, the cyclic dinucleotide synthase is DncV. In some embodiments, the DncV is E. coli DncV. In some embodiments, the DncV is V. cholerae DncV. In some embodiments, the DncV is P. aeruginosa DncV. In some embodiments, the DncV is X. citri DncV. In some embodiments, the cyclic dinucleotide synthase is DncV2. In some embodiments, the DncV2 is V. cholerae DncV2. In some embodiments, the cyclic dinucleotide synthase is disA. In some embodiments, the disA is B. subtilis disA. In some embodiments, the cyclic dinucleotide synthase is dacA. In some embodiments, the dacA is L. monocytogenes dacA. In someembodiments, the cyclic dinucleotide synthase is WspR. In some embodiments, the WspR is P. aeruginosa WspR.
[0204] cGAS is a well characterized immune sensor protein that acts to protect eukaryotic cells from bacterial and viral infection. The protein senses single stranded or double stranded DNA in the cytoplasm and catalyzes the synthesis of cGAMP. cGAMP then acts as a messenger molecule and activates Stimulator of Interferon Genes (STING) to trigger the production of type-I interferons (e.g., interferons beta and alpha). In some embodiments, cGAS is mammalian cGAS. In some embodiments, cGAS is human cGAS. In some embodiments, cGAS is mouse cGAS. In some embodiments, cGAS is a eukaryotic protein. In some embodiments, cGAS is a mammalian protein.
[0205] In some embodiments, the immune sensor protein is a prokaryotic protein. In some embodiments, cyclic dinucleotide synthase is a bacterial protein. In some embodiments, the bacterium is selected from V. cholerae, E. coli, B. subtilis, L. monocytogenes and P. aeruginosa.
[0206] According to some embodiments, the constitutively active cGAS comprises a cGAS that constitutively catalyzes Cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) synthesis, constitutively produces cyclic dinucleotides (CDNs) or both. In some embodiments, a constitutively active cGAS is a mutant cGAS. In some embodiments, the mutant cGAS comprises a single mutation. In some embodiments, a constitutively active cGAS comprises multiple mutations. In some embodiments, a constitutively active cGAS mutant, including full-length cGAS or a fragment which is N-terminal truncated.
[0207] In some embodiments, the immune sensor is RIGI. RIGI is also known as DDX58 and is a well characterized immune sensor protein that acts to protect eukaryotic cells from bacterial and viral infection. The protein senses aberrant (e.g., uncapped) RNA in the cytoplasm and via its adapter protein MAVS triggers the production of type-I interferons (e.g., interferons beta and alpha). In some embodiments, RIGI is mammalian RIGI. In some embodiments, RIGI is human RIGI.
[0208] In some embodiments, the immune sensor is MDA5. MDA5 is a well characterized immune sensor protein that acts to protect eukaryotic cells from bacterial and viral infection. The protein senses aberrant (e.g., double stranded) RNA in the cytoplasm and via its adapter protein MAVS triggers the production of type-I interferons (e.g., interferon beta). In some embodiments, MDA5 is mammalian MDA5. In some embodiments, MDA5 is human MDA5.
[0209] In some embodiments, constitutively active RIG-I or MDA5 mutants mimic viral RNA recognition, leading to persistent MAVS activation and robust induction of Type I IFNs. In certain embodiments, these mutants bypass viral immune evasion strategies and serve as potential antiviral or immunostimulatory agents.
[0210] In some embodiments, the immune sensor is IRF3. IRF3 is a well characterized immune sensor protein that acts to protect eukaryotic cells from bacterial and viral infection. IRF3 is found in the cytoplasm as an inactive form but upon serine / threonine phosphorylation forms a complex with CREBBP which translocates into the nucleus and transcriptionally activates interferons alpha and beta, and interferon-induced genes. In some embodiments, IRF3 is mammalian IRF3. In some embodiments, IRF3 is human IRF3. In some embodiments, IRF3 is porcine IRF3.
[0211] In some embodiments, the immune sensor is MAVS. MAVS is a well characterized adapter protein for immune sensor protein. The protein binds to activated RIGI-like immune sensors (e.g., MDA5 as well) then triggers the production of type I interferons (e.g., interferon beta). In some embodiments, MAVS is mammalian MAVS. In some embodiments, MAVS is human MAVS. In some embodiments, the MAVS mutant is a constitutively active variant that undergoes spontaneous oligomerization, leading to continuous activation of TBK1-IRF3 and NF-KB pathways and sustained Type I interferon (IFN-ot / p) production.
[0212] In some embodiments, the MAVS mutant comprises a CARD (Caspase Activation and Recruitment Domain) mutated to enhance CARD-CARD interactions, promoting ligand-independent signaling. In some embodiments, the MAVS mutant is a fragment containing only the CARD domain, which is constitutively active and capable of initiating downstream immune signaling in the absence of cytosolic RNA. In some embodiments, the MAVS mutant is a constitutively active immune sensor protein of the invention. In some embodiments, the MAVS mutant is a variant of the invention.
[0213] In some embodiments, a constitutively active MAVS mutant, including full-length MAVS or a CARD-only fragment, promotes spontaneous CARD-CARD oligomerization, leading to persistent activation of the TBK1-IRF3 pathway and continuous IFN-a / p production.
[0214] In some embodiments, the immune sensor is a constitutively active immune sensor. In some embodiments, a variant is a constitutively active variant. In some embodiments, the cGAS is a constitutively active cGAS. In some embodiments, the RIGI is constitutivelyactive RIGI. In some embodiments, the MDA5 is constitutively active MDA5. In some embodiments, the variant is a constitutively active variant. In some embodiments, constitutively active comprises catalyzing CDN synthesis constitutively. In some embodiments, constitutively active comprises constitutive activation of STING. In some embodiments, constitutively active comprises constitutive activation of MAVS. In some embodiments, interferon is a type I interferon. In some embodiments, interferon is interferon beta. In some embodiments, interferon is interferon alpha. In some embodiments, constitutively is in the absence of DNA. In some embodiments, DNA is single stranded DNA. In some embodiments, DNA is double stranded DNA. In some embodiments, DNA is cytosolic DNA. In some embodiments, constitutively is in the absence of uncapped RNA.
[0215] In some embodiments, the CAR binds to a surface antigen on a target cell. In some embodiments, the CAR is specific to a surface antigen on a target cell. In some embodiments the CAR antigen binding domain binds to a surface antigen on a target cell. In some embodiments, the target cell is in a subject. In some embodiments, the target cell is a disease cell. In some embodiments, the subject is in need of a method of the invention. In some embodiments, the subject suffers from a disease. In some embodiments, the disease is characterized by a pathological cell. In some embodiments, the target cell is a pathological cell. In some embodiments, the disease is treatable by inducing an immune response. In some embodiments, the immune response is an immune response against the target cell. In some embodiments, the disease is a proliferative disease. In some embodiments, the proliferative disease is cancer. In some embodiments, the cancer is a solid cancer. As used herein "cancer" or "pre -malignancy" are diseases associated with cell proliferation. In some embodiments, the cancer is selected from hepato-biliary cancer, brain cancer (e.g., glioblastoma), cervical cancer, urogenital cancer (e.g., urothelial cancer), testicular cancer, prostate cancer, thyroid cancer, ovarian cancer, nervous system cancer, ocular cancer, lung cancer, soft tissue cancer (e.g., synovial sarcoma and liposarcoma), bone cancer, pancreatic cancer, bladder cancer, skin cancer, intestinal cancer, hepatic cancer, rectal cancer, colorectal cancer, MSS colorectal cancer, MSI-low colorectal cancer, esophageal cancer, gastric cancer, gastroesophageal cancer, breast cancer (e.g., triple negative breast cancer), renal cancer (e.g., renal carcinoma), skin cancer, head and neck cancer, leukemia and lymphoma. In some embodiments, the cancer is selected from breast cancer and ovarian cancer. In some embodiments, the cancer is not characterized by the presence of cytoplasmic DNA. In some embodiments, the DNA is single stranded. In some embodiments, the DNA is double stranded.
[0216] In some embodiments the immune cell is a white blood cell. In some embodiments, the immune cell is a leukocyte. In some embodiments, a leukocyte is a lymphocyte or a myeloid cell. In some embodiments, the cell is a CD45+ cell. In some embodiments, the white blood cell (CD45+ cell) expresses Granzyme and / or Perforin. In some embodiments, the immune cell is characterized by the ability to form an immune synapse with a target cell. In some embodiments, the immune cell is a lymphocyte. In some embodiments, the immune cell is a myeloid cell. In some embodiments, the immune cell is selected from a lymphocyte and a myeloid cell. In some embodiments, the lymphocyte is a T cell. In some embodiments, the lymphocyte is an NK cell. In some embodiments, a cell that can form an immune synapse is selected from a T cell, an NK cell, a B cell, a mast cell, a neutrophil and a macrophage. In some embodiments, the T cell is a CD8+ T cell. In some embodiments, the T cell is a CD4+ T cell. In some embodiments, the T cell is a cytotoxic T cell. In some embodiments, the immune cell is selected from an NK cell and a CD8 T cell. In some embodiments, the T cell is selected from a CD4+ T cell, a CD8+ T cell. In some embodiments, the immune cell is selected from a regulatory T cell, a natural killer (NK) cell, an NKT cell, a gamma-delta T cell, a CAR-T cell, a TCR-T cell, and a tumor-infiltrating lymphocyte (TIL).
[0217] As used herein, the terms “immune synapse” and “immunological synapse” are used interchangeably and refer to a physical interface between an immune cell and a target cell, which is often an antigen-presenting cell. In some embodiments, the immune synapse is comprised of a supramolecular activation cluster. In some embodiments, the immune synapse comprises three concentric rings of protein clusters that mediate transfer of proteins between the immune cell and its target. In some embodiments, the immune synapse comprises adhesion molecules in the periphery. It will be understood by a skilled artisan that the adhesion molecules of the immunological synapse result in increased avidity and sustained contact between effector and target cell. This increased avidity / contact enables more potent and durable transport of molecules. In this way immune synapse formation produces a solution to the problem of successful and efficient transfer of therapeutic molecules. In some embodiments, the immune synapse comprises a high density of T cell receptors and co-stimulatory molecules. In some embodiments, the high density is in the center of the immunological immune synapse. In some embodiments, immune synapse formation triggers immune cell activation. In some embodiments, immune synapse formation triggers lymphocyte activation. In some embodiments, immune synapse formation triggers T cell activation. In some embodiments, activation is activation above a minimumthreshold needed for execution of effector function. In some embodiments, activation is activation above or equal to artificial activation by an anti-CD3 antibody.
[0218] In some embodiments, the immune cell is a cell of adoptive cell transfer. In some embodiments, the immune cell is for use in adoptive cell transfer. In some embodiments, the immune cell is a therapeutic cell. In some embodiments, the immune cell is a tumor infiltrating lymphocyte (TIL). In some embodiments, the immune cell is intended for an adoptive T cell therapy. In some embodiments, the immune cell is intended for an adoptive NK cell therapy. In some embodiments, the immune cell is modified to express a CAR and / or TCR. In some embodiments, the immune cell naturally expresses a TCR. In some embodiments, the CAR cell is a CAR T cell. In some embodiments, the CAR cell is a CAR NK cell. In some embodiments, the delivery cell is a cell in culture. In some embodiments, the delivery cell has been expanded. In some embodiments, the delivery cell is in vivo.
[0219] In some embodiments, the cell is modified to express the fusion CCL5 bound to the immune sensor protein. In some embodiments, the cell is modified to express the fusion CCL5 bound to cyclic dinucleotide synthase. In some embodiments, the cell is modified to express the fusion CCL4 bound to the immune sensor protein. In some embodiments, the cell is modified to express the fusion CCL4 bound to cyclic dinucleotide synthase. In some embodiments, the cell is modified to express the fusion CCL3 bound to the immune sensor protein. In some embodiments, the cell is modified to express the fusion CCL3 bound to cyclic dinucleotide synthase. In some embodiments, the modification is performed in-vitro or ex- vivo. In some embodiments, the modification is performed in vivo. In some embodiments, the modification is performed by introduction of the immune sensor protein or a nucleotide sequence encoding the immune sensor protein. In some embodiments, the modification is performed by introduction of the cyclic dinucleotide synthase or a nucleotide sequence encoding the cyclic dinucleotide synthase. In vitro introduction of a molecule of interest to cells is well known in the art and may be performed for a non-limiting example by electroporation, transfection, infection, by plasmid, virus and liposomes. In some embodiments, the modification is performed by introducing a nucleotide sequence and / or molecule (e.g., DNA and RNA) to be expressed in the lymphocyte. In some embodiments, expressing the immune sensor protein is expressing a fusion protein comprising the immune sensor protein. In some embodiments, expressing the cyclic dinucleotide synthase is expressing a fusion protein comprising the cyclic dinucleotide synthase.
[0220] By another aspect, there is provided a composition comprising a fusion protein of the invention.
[0221] By another aspect, there is provided a composition comprising a fusion protein of the invention and a CAR or exogenous TCR.
[0222] By another aspect, there is provided a composition comprising a nucleic acid molecule of the invention.
[0223] By another aspect, there is provided a composition comprising a nucleic acid molecule of the invention and a nucleic acid molecule encoding a CAR or exogenous TCR.
[0224] By another aspect, there is provided a composition comprising an immune cell of the invention.
[0225] In some embodiments, the composition is a therapeutic composition. In some embodiments, the comprising is a pharmaceutical composition. In some embodiments, the composition is for use in a method of the invention. In some embodiments, the composition is for use in treating a disease. In some embodiments, the composition is for use in treating cancer. In some embodiments, the composition is for use in inducing an immune response. In some embodiments, the composition is for use in treatment in a subject in need thereof. In some embodiments, the immune response is against a target cell. In some embodiments, the immune response is against a cell expressing a surface antigen that is bound by the CAR.
[0226] In some embodiments, a pharmaceutical composition comprises a pharmaceutically acceptable carrier, excipient, or adjuvant. As used herein, the term “carrier,” “adjuvant” or “excipient” refers to any component of a pharmaceutical composition that is not the active agent. As used herein, the term “pharmaceutically acceptable carrier” refers to non-toxic, inert solid, semi-solid liquid fdler, diluent, encapsulating material, formulation auxiliary of any type, or simply a sterile aqueous medium, such as saline. Some examples of the materials that can serve as pharmaceutically acceptable carriers are sugars, such as lactose, glucose and sucrose, starches such as com starch and potato starch, cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt, gelatin, talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols, such as propylene glycol, polyols such as glycerin, sorbitol, mannitol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate, agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline, Ringer's solution; ethyl alcohol and phosphate buffer solutions, as well as other non-toxic compatible substances used in pharmaceutical formulations. Some nonlimiting examples of substances which can serve as a carrier herein include sugar, starch,cellulose and its derivatives, powered tragacanth, malt, gelatin, talc, stearic acid, magnesium stearate, calcium sulfate, vegetable oils, polyols, alginic acid, pyrogen-free water, isotonic saline, phosphate buffer solutions, cocoa butter (suppository base), emulsifier as well as other non-toxic pharmaceutically compatible substances used in other pharmaceutical formulations. Wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents, excipients, stabilizers, antioxidants, and preservatives may also be present. Any non-toxic, inert, and effective carrier may be used to formulate the compositions contemplated herein. Suitable pharmaceutically acceptable carriers, excipients, and diluents in this regard are well known to those of skill in the art, such as those described in The Merck Index, Thirteenth Edition, Budavari et al., Eds., Merck & Co., Inc., Rahway, N.J. (2001); the CTFA (Cosmetic, Toiletry, and Fragrance Association) International Cosmetic Ingredient Dictionary and Handbook, Tenth Edition (2004); and the “Inactive Ingredient Guide,” U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Office of Management, the contents of all of which are hereby incorporated by reference in their entirety. Examples of pharmaceutically acceptable excipients, carriers and diluents useful in the present compositions include distilled water, physiological saline, Ringer's solution, dextrose solution, Hank's solution, and DMSO. These additional inactive components, as well as effective formulations and administration procedures, are well known in the art and are described in standard textbooks, such as Goodman and Gillman’s: The Pharmacological Bases of Therapeutics, 8th Ed., Gilman et al. Eds. Pergamon Press (1990); Remington’s Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, Pa. (1990); and Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins, Philadelphia, Pa., (2005), each of which is incorporated by reference herein in its entirety. The presently described composition may also be contained in artificially created structures such as liposomes, ISCOMS, slow-releasing particles, and other vehicles which increase the half-life of the peptides or polypeptides in serum. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. Liposomes for use with the presently described peptides are formed from standard vesicleforming lipids which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally determined by considerations such as liposome size and stability in the blood. A variety of methods are available for preparing liposomes as reviewed, for example, by Coligan, J. E. et al, Current Protocols in Protein Science, 1999, John Wiley & Sons, Inc., New York, and see also U.S. Pat. Nos.4,235,871, 4,501,728, 4,837,028, and 5,019,369.
[0227] The carrier may comprise, in total, from about 0.1% to about 99.99999% by weight of the pharmaceutical compositions presented herein.
[0228] In some embodiments, the composition comprises the fusion protein and the CAR. In some embodiments, the composition comprises a single nucleic acid molecule that encodes both the fusion protein and the CAR. In some embodiments, the nucleic acid molecule comprises a single open reading frame that encodes the fusion protein and the CAR. In some embodiments, the single open reading frame encodes a ribosome skipping peptide or an IRES between a sequence encoding the fusion protein and a sequence encoding the CAR.
[0229] In some embodiments, the single open reading frame encodes SEQ ID NO: 172 (CCL5_calpain linker (caplainL)_MAVS_2CARD_Furin-GSG-T2A_CAR-HER2; 10_510). In some embodiments, the single open reading frame encodes SEQ ID NO: 173 (CCL5_calpain linker (caplainL)_MAV S_2CARD_ hisCPP_Furin-GSG-T2A_CAR-HER2; 10 511). In some embodiments, the single open reading frame encodes SEQ ID NO: 174 (CCL5_AAWVA_calpainL_MAVS_2CARD _Furin-GSG-T2A_CAR-HER2; 10_696). In some embodiments, the single open reading frame encodes SEQ ID NO: 175 (CCL5_calpainL_mcGAS_stabilized _noNterm_Furin-GSG-T2A_CAR-HER2; 10 526). In some embodiments, the single open reading frame encodes SEQ ID NO: 176 (CCL5_calpainL_IFNb_Furin-GSG-T2A_CAR-HER2; 10 705). In some embodiments, the single open reading frame encodes SEQ ID NO: 177 (CCL5_calpainL_MAVS_2CARD optimized_Furin-GSG-T2A_CAR-HER2; 10 893). In some embodiments, the single open reading frame encodes SEQ ID NO: 178 (CCL5_calpainL_ MAVS_CARD_G78K_Furin-GSG-T2A CAR-HER2; 10 1091). In some embodiments, the single open reading frame encodes SEQ ID NO: 179 (CCL5_calpainL_ MAVS_CARD_V82K_Furin-GSG-T2A CAR-HER2; 10 1092). In some embodiments, the single open reading frame encodes SEQ ID NO: 180 (CCL5_calpainL_ MAVS CARD S90K_Furin-GSG-T2A_CAR-HER2; 10 1093). In some embodiments, the single open reading frame encodes SEQ ID NO: 181 (CCL5_calpainL_ MAVS_CARD_G78K_S90K_Furin-GSG-T2A_CAR-HER2; 10 1094). In some embodiments, the single open reading frame encodes SEQ ID NO: 182 (CCL5_calpainL_ MAVS_CARD_V82K_S90K_Furin-GSG-T2A_CAR-HER2; 10 1095). In some embodiments, the single open reading frame encodes SEQ ID NO: 183 (CCL5_calpainL_MAVS_CARD_G78K_V82K_Furin-GSG-T2A_CAR-HER2 ; 10 1096). In some embodiments, the single open reading frame encodes SEQ ID NO: 184 (CCL5_AAWVA_calpainL_MAVS_CARD_Furin-GSG-T2A_CAR-HER2). In someembodiments, the single open reading frame encodes SEQ ID NO: 185 (CCL5_K33A_calpainL_MAVS_CARD_Furin-GSG-T2A_CAR-HER2). In some embodiments, the single open reading frame encodes SEQ ID NO: 186 (CCL5_allA_calpainL_MAVS_CARD_Furin-GSG-T2A_CAR-HER2). In some embodiments, the single open reading frame encodes SEQ ID NO: 187 (CCL5_cut8aa_calpainL_MAVS_CARD_Furin-GSG-T2A_CAR-HER2). In some embodiments, the single open reading frame encodes SEQ ID NO: 188 (CCL5_AANA_AAWVA_calpainL_MAVS_CARD_Furin-GSG-T2A_CAR-HER2) . In some embodiments, the single open reading frame encodes SEQ ID NO: 189 (CCL5_K33V_calpainL_MAVS_CARD_Furin-GSG-T2A_CAR-HER2; 10 1208). In some embodiments, the single open reading frame encodes SEQ ID NO: 190 (CCL5_D6A_calpainL_MAVS_CARD_Furin-GSG-T2A_CAR-HER2). In some embodiments, the single open reading frame encodes SEQ ID NO: 191 (CCL5_S4A_calpainL_MAVS_CARD_Furin-GSG-T2A_CAR-HER2). In some embodiments, the single open reading frame encodes SEQ ID NO: 192 (CCL5_SlA_S4A_calpainL_MAVS_CARD_Furin-GSG-T2A_CAR-HER2). In some embodiments, the single open reading frame encodes SEQ ID NO: 193 (CCL5_T7K_calpainL_MAVS_CARD_Furin-GSG-T2A_CAR-HER2). In some embodiments, the single open reading frame encodes SEQ ID NO: 194 (CCL5_C10S_C34S_calpainL_MAVS_CARD_Furin-GSG-T2A_CAR-HER2). In some embodiments, the single open reading frame encodes SEQ ID NO: 195 (CCL5_F12Y_calpainL_MAVS_CARD_Furin-GSG-T2A_CAR-HER2). In some embodiments, the single open reading frame encodes SEQ ID NO: 196 (CCL5_F12W_calpainL_MAVS_CARD_Furin-GSG-T2A_CAR-HER2). In some embodiments, the single open reading frame encodes SEQ ID NO: 197 (CCL5_AANA_calpainL_MAVS_CARD_Furin-GSG-T2A_CAR-HER2). In some embodiments, the single open reading frame encodes SEQ ID NO: 198 (CCL5_M5_calpainL_MAVS_CARD_Furin-GSG-T2A_CAR-HER2). In some embodiments, the single open reading frame encodes SEQ ID NO: 199 (CCL5_E66S_calpainL_MAVS_CARD_Furin-GSG-T2A_CAR-HER2). In some embodiments, the single open reading frame encodes SEQ ID NO: 200 (CCL4_F13A_calpainL_MAVS_CARD_pos_Furin-GSG-T2A_CAR-HER2; 10 1181). In some embodiments, the single open reading frame encodes SEQ ID NO: 201 (CCL4_cut6aa_calpainL_MAVS_CARD_pos_Furin-GSG-T2A_CAR-HER2; 10 1182). In some embodiments, the single open reading frame encodes SEQ ID NO: 202(CCL4_L34A_calpainL_MAVS_CARD_pos_Furin-GSG-T2A_CAR-HER2; 10 1184). In some embodiments, the single open reading frame encodes SEQ ID NO: 203 (CCL4_allA_calpainL_MAVS_CARD_pos_Furin-GSG-T2A_CAR-HER2; 10 1185). In some embodiments, the single open reading frame encodes SEQ ID NO: 204 (CCL4_AAWVA_calpainL_MAVS_CARD_pos_Furin-GSG-T2A_CAR-HER2;10 1187). In some embodiments, the single open reading frame encodes SEQ ID NO: 205 (CCL4_calpainL_MAVS_CARD_pos_Furin-GSG-T2A_CAR-HER2; 10 960). In some embodiments, the single open reading frame encodes SEQ ID NO: 206 (CCL3_Q33A_calpainL_MAVS_CARD_pos_Furin-GSG-T2A_CAR-HER2; 10 1175). In some embodiments, the single open reading frame encodes SEQ ID NO: 207 (CCL3_AAWVA_calpainL_MAVS_CARD_pos_Furin-GSG-T2A_CAR-HER2;10 1178). In some embodiments, the single open reading frame encodes SEQ ID NO: 208 (CCL3_calpainL_MAVS_CARD_pos_Furin-GSG-T2A_CAR-HER2; 10 959). In some embodiments, the single open reading frame encodes SEQ ID NO: 209 (CCL4_G4SX3_MAVS_CARD_G78K_Furin-GSG-T2A_CAR-HER2; 10 1306). In some embodiments, the single open reading frame encodes SEQ ID NO: 210 (CCL4_AAWVA_G4SX3_MAVS_CARD_G78K_Furin-GSG-T2A_CAR-HER2;10 1307). In some embodiments, the single open reading frame encodes SEQ ID NO: 211 (CCL3_G4SX3_MAVS_CARD_G78K_Furin-GSG-T2A_CAR-HER2; 10 1344). In some embodiments, the single open reading frame encodes SEQ ID NO: 212 (CCL5_K33V_G4Sx3_MAVS_CARD_G78K_Furin-GSG-T2A_CAR-HER2; 10 1214). In some embodiments, the single open reading frame encodes SEQ ID NO: 213 (CCL5_G4Sx3_MAVS_CARD_G78K_Furin-GSG-T2A_CAR-HER2; 10 1216).
[0230] By another aspect, there is provided a method of inducing an immune response in a subject, the method comprising administering to the subject a composition of the invention, thereby inducing an immune response in a subject.
[0231] In some embodiments, the subject is a mammal. In some embodiments, the mammal is a human. In some embodiments, the subject is in need of a method of the invention. In some embodiments, the subject suffers from a disease. In some embodiments, the method further comprises selecting the subject. In some embodiments, the subject suffers from cancer. In some embodiments, the subject suffers from an infection. In some embodiments, the infection is a viral infection. In some embodiments, the infection is a bacterial infection. In some embodiments, the disease comprises a disease cell that expresses a surface antigen that is bound by the CAR. In some embodiments, the disease can be treated by killing adisease cell that expresses a surface antigen that is bound by the CAR. In some embodiments, the disease is cancer and the antigen is HER2. In some embodiments, the disease is cancer and the antigen is CLDN6. In some embodiments, the disease is cancer and the antigen is LY6G6D. Other cancer antigens and CARs that target those antigens are well known in the art and a skilled artisan can select the CAR that is appropriate for treating a specific cancer. In some embodiments, the cancer is a solid cancer. In some embodiments, the cancer is a tumor. In some embodiments, the cancer is selected from breast cancer and ovarian cancer. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is colon cancer.
[0232] In some embodiments, the subject suffers from a disease treatable by inducing interferon-beta (IFNb) expression. In some embodiments, the disease is multiple sclerosis (MS). In some embodiments, the method is a method of treating MS. In some embodiments, the cell is targeted to the central nervous system (CNS). In some embodiments, the cell comprises a CAR that binds an antigen in the CNS. In some embodiments, the CNS is the brain. In some embodiments, the cell comprises a CAR that binds CD 19.
[0233] As used herein, the terms “administering,” “administration,” and like terms refer to any method which, in sound medical practice, delivers a composition containing an active agent to a subject in such a manner as to provide a therapeutic effect. One aspect of the present subject matter provides for intravenous administration of a therapeutically effective amount of a composition of the present subject matter to a patient in need thereof. Other suitable routes of administration can include parenteral, subcutaneous, oral, intramuscular, intratumoral or intraperitoneal.
[0234] The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.EXAMPLES
[0235] Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watsonet al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J. E., ed. (1994); "Culture of Animal Cells - A Manual of Basic Technique" by Freshney, Wiley-Liss, N. Y. (1994), Third Edition; "Current Protocols in Immunology" Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by reference. Other general references are provided throughout this document.Materials and Methods
[0236] Preparation of T cell stably expressing Edity construct (Edity T cells): PBMC were thawed, and following 4h recovery at 37° C, T cells were activated using TransAct (Miltenyi Biotec). After 24-48h the cells were transduced with lentivirus expressing the relevant construct. The cells were left with the virions for a 24h-48h incubation followed by T cell expansion for an additional 4-6 days. Stable expression of the construct was confirmed by measuring expression levels of the gene of interest at day 7-9. The level of CAR expression was measured by FACS using fluorescently labelled Anti-Trastuzumab (Anti-Idiotype) Antibody. MAVS protein levels were also detected by FACS using fluorescently labelled anti-MAVS antibody.
[0237] Coculture assay: For engineered T cell co-culture with target cells, the target cells were prepared by detaching (if adherent), counting, and seeding in a 96-well plate at a density of 5-10 x 10A4 cells / well. CAR T cells were harvested, washed, and counted before being added at varying effector-to-target (E:T) ratios (1:1 to 4:1). Control wells included target cells alone, and engineered T cells alone. Co-cultures were incubated at 37°C with 5% CO2 for 24 hours. Cytotoxicity was assessed using LDH release assays, annexin V / PI flow cytometry, and live-cell imaging, while IFNb release was quantified using ELISA or Hek Blue cells reporter assay. Flow cytometry analysis was conducted to evaluate viability, construct expression and proliferation. Data were normalized to control conditions, and dose-response curves were analyzed using appropriate statistical software. Experimental conditions, including seeding densities and media composition, were optimized, and appropriate controls were included to confirm CAR specificity.
[0238] Type I interferon signaling by IFNb detection: IFNb in medium was measured in medium from the coculture assay and from T cells only culture that were seeded at the same time and concentration as in the coculture.
[0239] The IFNb levels were measured by both Human IFNb ELISA (R&D systems) according to the manufacturer’s instruction, and by HEK-Blue IFN-a / p assay (Invivo gen) according to the manufacturer’s instructions. The HEK-Blue IFN-a / p assay is specifically designed to monitor the activation of the JAK-STAT pathway induced by type I IFNs. The activation of this pathway is made detectable by the addition of a reporter gene expressing a secreted embryonic alkaline phosphatase (SEAP). SEAP which is secreted in the supernatant is easily detectable when using QUANTI-BlueTM Solution, a SEAP detection reagent.
[0240] In vivo study: To demonstrate that engineered T cells expressing fusion constructs of the invention lead to delayed tumor growth as compared to engineered T cells expressing a non-active sensor, tumor-bearing mice are treated with T cells either expressing the active or non-active constructs or left untreated as controls.
[0241] Forin vivo efficacy, mice are injected subcutaneously (S.C.) or intraperitoneally (IP) with a tumor cell suspension containing 0.1-5 million cells, either expressing or not expressing luciferase, and tumor growth is monitored twice weekly. For S.C. tumors the volume measurement is initiated once palpable tumors are observed, and the tumor size is tracked using digital Vernier calipers. For I.P. tumors expressing luciferase, luminesce is monitored by IVIS device. After reaching a tumor volume of 100-200 mm3or the desired luminescence, mice are grouped and randomized into cages based on tumor volume and treated with engineered T cells expressing the constructs with either an active or non-active immune sensor that were prepared, cryopreserved, and revived for injection. Engineered T cells are then injected into the mice via intravenous (IV) or intraperitoneal (IP) routes, depending on the tumor model. Animals are monitored for clinical signs, body weight, and tumor growth at least twice weekly throughout the study. Any abnormal clinical signs, along with tumor size measurements, are recorded, and body weight is monitored at least twice weekly. Animals displaying severe clinical symptoms, a body weight reduction exceeding 20% from pre-test levels or clear signs of morbidity will be humanely euthanized in accordance with approved ethical guidelines. Similarly, mice bearing tumors of volumes exceeding 2000 mm3, or tumors with severe necrosis, or tumors that exceed 10% of the mouse's body weight will be euthanized in accordance with approved ethical guidelines.
[0242] Killing assay: Luciferase-expressing HCC target cells were prepared by detaching (if adherent), counting, and seeding in a 96-well plate at a density of 5 x 10A4 cells / well. CAR T cells were harvested, washed, and counted before being added at varying effector-to-target (E:T) ratios (1: 1 to 1:8). Control wells included Luciferase-expressing target cells alone. Cocultures were incubated at 37°C with 5% CO2 for 24 hours. Cytotoxicity was assessed using Luciferase assay system (Bio-Gio™, Promega) according to manufacturing instructions. Luminescence was measured using a plate-reading luminometer according to calibrated conditions. Luminescence data were normalized to control conditions, and analyzed using appropriate statistical software. Bio-Gio™ Luciferase Assay System is designed for using firefly luciferase reporter. Luciferase-expressing Target killing and cytotoxicity was assessed by evaluating the reduction in luminescence following CAR T cells co-culture.
[0243] Cytokine / chemokine panel: Co-culture assays were performed using CAR-T cells and HCC1954 target cells at an effector-to-target ratio of 4:1. Multiplex immunoassay designed for flow cytometry, allowing simultaneous quantification of multiple different soluble analytes (cytokines, chemokines) was used (LEGENDplex™, Biologend). After 24 h of co-culture, supernatants were collected and either analyzed directly for level of IFNa, TARC and IP 10 levels or transferred onto M2 -polarized macrophages for an additional 24 h incubation. Conditioned media from these secondary M2 cultures were then harvested and subjected to the same LEGENDplex panels to assess cytokine and chemokine profiles under conditions with or without M2 macrophages.Example 1: Fusion of a constitutively active immune sensor to CCL5 and expression with an anti-cancer CAR
[0244] Mitochondrial antiviral-signaling protein (MAVS) is a key regulatory in antiviral innate immunity. When active it induces transcription of interferon regulatory factors such as IRF3, which leads to type I interferon production and secretion. The MAVS CARD domain is known to be the active domain and a mutant MAVS containing just the CARD domain is known to be constitutively active. A proprietary MAVS CARD domain mutant termed MAVS_CARD3mut was generated (SEQ ID NO: 30, G77K, V81K, S89K triple mutant).
[0245] Chemokine ligand 5 (CCL5, also known as RANTES) was suggested to be constitutively transcribed and translated in T cells and then stored in a specialized (non-lytic) vesicle. Upon T cell stimulation and cancer cell synapse formation the vesicle is remodeled and CCL5 is released. For this reason, CCL5 was selected as the initial chemokine to test,although other chemokines, especially those also stored in vesicles, are also tested (see Table 1 and Example 2). It was hypothesized that the fusion protein would also be stored in the vesicle and would only be released and become active upon cancer cell engagement. The constitutively active interferon regulatory protein was tested in a fusion with a chemokine (CCL5), although other constitutively active immune sensor proteins are also tested (see Table 2, sequences are without an N-terminal methionine). CLL5 (SEQ ID NO: 5) was placed N-terminal to the MAVS_CARD3mut and was separated by a linker sequence (SEQ ID NO: 36) producing the fusion protein provided in SEQ ID NO: 37. A construct with a GGGGS linker was also produced and tested.
[0246] Table 1: Chemokines of the CCL familyName Source SEQ ID NO: Entrez gene ID UniprotCCL1 Human 1 6346 P22362CCL2 Human 2 6347 P13500CCL3 Human 3 6348 P10147CCL4 Human 4 388372 Q8NHW4CCL5 Human 5 6352 P13501CCL6 Mouse 6 20305 P27784CCL7 Human 7 6354 P80098CCL8 Human 8 6355 P80075CXCL3 Human 9 2921 P19876CCL9 Mouse 10 20308 P51670CCL 11 Human 11 6356 P51671CCL 12 Mouse 12 20293 Q62401CCL 13 Human 13 6357 Q99616CCL 14 Human 14 6358 QI 6627CCL 15 Human 15 6359 Q16663CCL 16 Human 16 6360 015467CCL 17 Human 17 6361 Q92583CCL18 Human 18 6362 P55774CCL19 Human 19 6363 Q99731CCL20 Human 20 6364 P78556CCL21 Human 21 6366 000585CCL22 Human 22 6367 000626CCL23 Human 23 6368 P55773CCL24 Human 24 6369 000175CCL25 Human 25 6370 015444CCL26 Human 26 10344 Q9Y258CCL27 Human 27 10850 Q9Y4X3CCL28 Human 28 56477 Q9NRJ30247] Table 2: Constitutively active immune sensors (without N-terminal methionine residues).Name SEQ ID NO:MAVS CARD WT 29MAVS_CARD3mut (G77K V81K S89K) 30MAVS CARDmut (G77K) 154RIGI 2CARD A52E 31mcGAS MUT 1 32hcGAS_E225A_D227A 33mcGAS_MUT2 34hlFNb 162hMDA5_M854K Mut 166hDMA5 2CARD 167hMDA5_G821S Mut 168hIRF3_5D Mut 169hIRF3_5E Mut 170IRF7 / IRF3 fusion_5D Mut 171
[0248] The fusion protein construct was tested in T cells expressing a trastuzumab-based CAR and with HCC1954 cancer cells, as before. In order to ensure that the T cells express both the fusion protein and the CAR, a single open reading frame was produced in which a sequence coding for a furin cleavage site and the T2A ribosome skipping peptide was inserted between the coding region for the fusion protein and the CAR coding region. The use of both the cleavage site and the ribosome skipping peptide ensures the production of two separate polypeptides. This is essential as the CAR must be inserted into the plasma membrane of the cell and the fusion protein is not meant to be membrane bound. This construct was called 10_510 (SEQ ID NO: 39). A very similar construct which included a histidine replaced cell penetrating peptide (hisCPP) before the furin cleavage site was also produced and expressed in T cells (10 511; SEQ ID NO: 41). The hisCPP is known as an endosomal escape peptide, and it was added to test if this feature enhanced fusion protein release of the immune sensor signaling pathway protein if at some point it will be entrapped in endosomes.
[0249] PBMCs were made to stably express the 10_510 construct or the 10 511 construct as described in the Materials and Methods section. First, a western blot was run to confirm that the fusion protein is constitutively produced regardless of T cell activation status. A construct with just the CAR (6 118) was used as a control. Very high levels of MAVS fusion protein (~23 kDa) were detected only when the 10 510 construct was added (Fig. 1). The experiment was also run in MAVS knockout cells and CCR5 knockout cells. In both cases robust MAVS fusion protein was detected even without T cell activation (Fig. 1).
[0250] Next, the wild-type T cells containing the fusion protein constructs were cocultured with HCC1954 target cells at an E:T ratio of 4:1 or were cultured alone. As a negative control, two constructs were made to parallel 10 510 and 10 511 in which the MAVS_CARD3mut sequence was replaced in the fusion protein by GFP. These constructs were called 0_541 and 0_542 respectively and were also expressed in effector cells. The CAR alone (6 118) was also expressed in effector cells.
[0251] After 24 hours of either solo culture or coculture with the cancer cells, the type I interferon response was evaluated by measurement of the levels of IFNb in the culture media as described in the Material and Methods section. Several other IFN responsive genes (IFNa, MX1, OAS1 and IFIT) were also measured by qPCR. Solo culture never produced significant levels of IFNb (Fig. 2A), indicating that the fusion protein remains sequestered as wild-type CCL5 does and is not free in the cytoplasm to induce the type I interferon response. Cancer coculture however produced robust IFNb expression in the coculture with effector cells expressing the fusion protein of the invention. The increase was of nearly two orders of magnitude, and was observed as early at 6 hours after the start of the coculture. This rapid response is possible because the MAVS mutant does not need to be transcribed and translated, rather it is merely released to the cytoplasm where it immediately activates the interferon type I pathway.
[0252] In this experiment, the hisCPP peptide demonstrated similar effect to that of the CCL5+MAVS_CARD3mut fusion construct. The control construct containing GFP (essentially CCL5 alone) did not produce this increase, and the CAR alone also did not produce such an increase even though the CAR would induce T cell activation. Rather, when the engineered immune cells were co-cultured with target cells, high levels of IFNb were detected in the supernatant due to the constitutively active MAVS. These results demonstrate that the CAR-T cells with the fusion protein are safe when they are not exposed to cancer cells (no interferon response activation), but that cancer recognition leads to rapid activation of the innate interferon response specifically in the vicinity of the cancer cells. In this way the superiority of the engineered cells over traditional CAR cells is readily apparent.
[0253] To test the importance of the MAVS_CARD triple mutant the same fusion protein construct was generated with full human MAVS. This fusion protein was found not to increase IFNb at all when cultured with cancer cells. A simpler MAVS_CARD with only the first mutation (G77K) (SEQ ID NO: 154), called MAVS CARDmut when part of the fusion protein with CCL5 (SEQ ID NO: 70) was also tested. Surprisingly, the single mutation MAVS_CARD produced more than 4 times greater IFNb secretion during coculture with cancer cells as compared to the triple mutant (Fig. 2B). Importantly, in the monoculture both constructs produced the same level of background secretion, indicating that the single mutant greatly increases IFNb, in an activation specific manner.
[0254] A similar experiment was run using cells expressing the single construct of the fusion protein and CAR (10 510) and cells expressing two separate constructs one encoding the fusion protein (10_502) and one encoding the CAR (6 118). A construct expressing thefusion protein but not the CAR was also tested. As expected, the combined construct and the separate constructs worked comparably well, producing a robust secretion of IFNb in the presence of cancer cells (Fig. 3). The fusion protein alone, without co-expression of the CAR, produced no such increase. When only the MAVS_CARD3mut part of the fusion ( 10_854) was expressed with the CAR (6 118) no significant increase in IFNb was observed (Fig. 4A). Similarly, when the MAVS_CARD3mut part of the fusion was in the same construct as the CAR (10 919) and was co-expressed with the CCL5 part of the fusion (5 182) or just the CCL5 was expressed with the CAR (6 118) no increase in IFNb was observed during coculture (Fig. 4B). This data taken together clearly shows that the fusion of the constitutively active protein to CCL5 is essential, but that the CAR can be on the same or a different construct.
[0255] In order to emphasize the importance of the constitutive MAVS, an inactive mutant was tested as part of the fusion protein. An E26R mutation in the MAVS_CARD3mut protein (SEQ ID NO: 42) has been shown to abolish signaling. This mutant was fused with CCL5 in a construct with the CAR to produce construct 10 754. This construct and the active MAVS_CARD3mut construct were tested in the HCC1954 cancer cells as well as a second cancer type, SKOV3 ovarian carcinoma cells (Fig. 5). The active MAVS construct produced robust IFNb expression in both cell types, while the inactive mutant produced only background levels of IFNb (see also in Fig. 4B).
[0256] Next, a mutant of CCL5 was tested in which its heparin binding site is mutated (SEQ ID NO: 45). This mutant has the 5 amino acids from position 55 to 59 (KKWVR-SEQ ID NO: 43) replaced with AAWVA (SEQ ID NO: 44). The CCL5-AAWVA was inserted into the fusion protein with the constitutively active MAVS and the CAR. This construct, 10_696, and the construct with the hisCPP (10 689) were both tested. These constructs were found to be fully functional and as good as the constructs with wild-type CCL5 (Fig. 6).
[0257] The constitutively active MAVS was used as a proof-of-concept of utilization of a constitutively active protein of the immune sensor signaling pathway / innate immune pathway in the fusion protein. In order to demonstrate that the functionality of the fusion protein with additional constitutively active proteins of the immune sensor signaling pathway / innate immune pathway, additional constructs were tested: 1. A construct comprising CCL5 and constitutively active cGAS and 2. A construct comprising CCL5 and IFNb (which is naturally constitutively active).
[0258] To this end, N-terminal truncation of a mutant mcGAS (cyclic GMP-AMP [cGAMP] synthase) was stabilized to produce constitutive expression (SEQ ID NO: 46). This protein was inserted in the fusion protein in the construct with the CAR (10_526; SEQ ID NO: 48). This construct produced an order of magnitude increase in IFNb in the culture media when coculture with cancer cells as compared to solo culture (Fig. 7). Further, IFNb (SEQ ID NO: 162) was inserted in the fusion protein in the construct with the CAR (10_705, SEQ ID NO 79). Notably, this construct produced robust IFNb, but only in the coculture. These examples prove that T cells expressing a fusion protein of CCL5 with a constitutively active immune senor signaling pathway protein of the interferon type I pathway produce a significant IFNb response when the T cells are activated by the antigen expressed on tumor cells.Example 2: Testing additional chemokines
[0259] The CCL (CC chemokine ligand) family is a major subgroup of chemokines directing the migration (chemotaxis) of immune cells. CC chemokines have two adjacent cysteine (C) residues near their N-terminus. This motif distinguishes them from other chemokine subfamilies such as CXC (which have a single amino acid between the first two cysteines), CX3C, and XC chemokines. CC chemokines act viaG protein-coupled receptors (CCR1-CCR10) on target cells, activating intracellular signaling that guides immune cell migration. Some chemokines (e.g., CCL2, CCL5) can also attract cells that suppress immunity, such as regulatory T cells (Tregs) or myeloid-derived suppressor cells (MDSCs), potentially dampening anti-tumor effects.
[0260] As the CCL family is known to sequester in non-lytic vesicles, constructs were created in which CCL5 was replaced with other CCL family members in a fusion protein with constitutive MAVS. T cells expressing these fusion proteins along with the trastuzumab-based CAR were cocultured and with HCC1954 cancer cells or were cultured alone. As before, IFNb levels in the supernatant were measured to determine the effectiveness of the fusion protein. The results are summarized in Table 3. All constructs along with the CAR were expressed well with the exception of CCL11 for which there was a technical issue. As can be seen in Table 3, CCLs induced increased IFN[3 secretion in coculture relative to T cells cultured alone. Specifically, CCL8 showed an approximately 11-fold increase, and mCCL12 showed an approximately 5-fold increase. Notably, CCL3, CCL4 and CCL5 all produced robust IFNb secretion when coculture was performed and more than an order of magnitude lower expression when the T cells were cultured alone. Thus, all 3 of these chemokines are effective as part of a fusion protein with a constitutively active protein of the immune sensor signaling pathway.
[0261] Table 3: IFNb levels in supernatant from T cells expressing fusion proteins of the invention cocultured (CC) with cancer cells or cultured alone (EO). Various CCL chemokines are tested as part of the fusion protein.Construe Fusion Protein SEQt ID NO: CCL %CAR CC EO10 957 80 CCL1 92% 17 1110 958 81 CCL2 90% 23 1210 959 82 CCL3 93% >8200 21210 960 83 CCL4 91% >8200 17610 510 37 CCL5 86% >8200 12810 961 84 mCCL6 95% 14 1210 962 85 CCL7 81% 14 1110 963 86 CCL8 94% 241 2110 964 87 CCL9 90% 26 2210 965 88 CCL 11 1% NA NA10 966 89 mCCL12 96% 192 3410 967 90 CCL 13 91% 45 2510 968 91 CCL 14 90% 29 2310 969 92 CCL 15 91% 24 2210 970 93 CCL 16 77% 23 1410 971 94 CCL 17 75% 20 1410 972 95 CCL 18 74% 22 1410 973 96 CCL 19 81% 21 1410 974 97 CCL20 82% 22 1410 975 98 CCL21 92% 23 1510 976 99 CCL22 66% 23 1410 977 100 CCL23 70% 29 2010 978 101 CCL24 81% 25 1910 979 102 CCL25 77% 31 1910 980 103 CCL26 81% 35 2010 981 104 CCL27 71% 31 1910 982 105 CCL28 58% 32 210262] In order to confirm that the incorporation of the fusion proteins of the invention do not alter the intrinsic killing of the T cells, CAR T cells were plated with luciferase labeled tumor cells at varying effector-to-target (E:T) ratios (1: 1 to 1:8) and killing was measured.
[0263] Table 4: Intrinsic killing by CAR-T cells expressing fusion proteins.1:1 1:2 1:4 1:8CCL5 (MAVSG77K) 2% 9% 23% 32%CCL5 (MAVSWT) 90 / Z / o 10% 25% 36%CCL4 (MAVSG77K) 90 / Z / o 7% 21% 29%CCL4 (MAVSWT) 90 / Z / o 8% 25% 35%CCL3 (MAVSG77K) 90 / / O 10% 26% 34%CCL3 (MAVSWT) 2% 9% 24% 34% Mock 100% 101% 95% 96%HCC-LUC only 102% 102% 106% 97%
[0264] The results indicate that the intrinsic killing potency of the CAR-T cells is not hampered by the fusion protein. Thus, in addition to the release of an immune response in the tumor microenvironment and recruitment of the immune intrinsic machinery, the CAR-T cells of the invention will also continue to kill target cells as other CAR-T cells do.
[0265] In order to confirm the modulation that the CAR-T cells expressing the fusion proteins induce on the tumor microenvironment, CAR-T cells expressing CCL3 / 4 / 5 fusion proteins of the invention were cultured with HCC1954 cancer cells at an effector-to-target ratio of 4:1. A multiplex panel was run (Table 5) and it was found that in addition to increased IFNb secretion there is also greatly increased interferon alpha (IFNa) secretion and also moderately increased secretion of the proinflammatory chemokine IP 10 (CXCL10). IFNa secretion indicates activation of the type I interferon response. In order to mimic the effects of this immune signaling on the tumor microenvironment, the supernatant from the coculture was transferred to a culture of macrophages that have been polarized to the M2 state, that represents the state of tumor associated macrophages. This transfer resulted in a significant reduction in the secretion of the chemokine TARC / CCL17 by the macrophages, while greatly increasing IP-10 levels (Table 5). IP-10 chemokine was shown to recruit effector populations such as NK, Thl and CD8 T cells. TARC / CCL17 recruits regulatory T cells (Tregs) and promotes Th2 polarization via binding to CCR4. This indicates that the M2 macrophages have been skewed toward a more proinflammatory phenotype. Further, acombination of IP- 10 increase coupled with CCL17 decrease would promote a transition to a more pro-inflammatory tumor microenvironment.
[0266] Table 5: Expression in supernatant from coculture of CAR-T cells and cancer cells with (M2) and without (No M) transfer to M2 macrophages culture.SEQ ID NO: IFN-a2of fusion pg / ml TARC pg / ml IP-10 pg / ml CCL4(MAVS G77K) 155 74 994 228,695 CCL4AAWVA(MAVS G77K) 156 98 921 310,672 CCL3(MAVS G77K) 157 89 999 279,426 CCL5M2 K33V(MAVSG77K) 158 104 1,055 315,235 CCL5(MAVS_G77K) 159 92 904 303,825 CCL4(inactiveMAVS) 160 1 2,099 156,252 CCL5(inactiveMAVS) 161 1 2,463 130,721 Mock - 1 147 929 CCL4(MAVS G77K) 155 65 110 12,108 CCL4AAWVA(MAVS G77K) 156 73 148 7,907 CCL3(MAVS G77K) 157 64 130 19,586 CCL5No MK33V(MAVSG77K) 158 83 381 4,080 CCL5(MAVS_G77K) 159 62 146 14,095 CCL4(inactiveMAVS) 160 1 193 781 CCL5(inactiveMAVS) 161 1 228 706Mock 3,669Example 3: Testing chemokine mutations
[0267] In order to explore the effectiveness of the CCL molecules various mutations were made in CCL3, CCL4 and CCL5 (see Table 6-8, sequences of mutant chemokines are provided in SEQ ID NO: 106-121, 138-142, 149-150). These mutant chemokines were incorporated into fusion proteins with the constitutively active MAVS (SEQ ID NO: 122-137, 143-148, 152-153) and then expressed with the CAR in T cells that were cultured alone or with cancer cells as before.
[0268] Table 6: CCL5 mutations and IFNb levels (pg / mL) in supernatant from T cells expressing fusion proteins of the invention cocultured (CC) with cancer cells or cultured alone (EO). Numbering is with respect to the WT CCL5 positioning after the 23 amino acid signal peptide.Mutation SEQ ID NO: Construct SEQ ID NO: CC EO WT 5 10 502 37 4720 198 AAWVA 106 10 825 122 5305 504 D6A 107 10 831 123 699 0 S4A 108 10 832 124 1607 0 S1A S4A 109 10 833 125 2480 0 T7K 110 10 834 126 399 0 CIOS C34S 111 10 835 127 97 0 K33V 112 10 1208 128 3534 23 K33A 113 10 836 129 3720 57 allA 114 10 837 130 2578 78 F12Y 115 10 838 131 873 0 F12W 116 10 839 132 551 0 AANA 117 10 840 133 291 0 M5 118 10 859 134 483 0 cut8aa 119 10 871 135 2145 0 E66S 120 10 877 136 629 0 AANA_AAWVA 121 10 878 137 3450 291
[0269] Table 7: CCL4 mutations and IFNb levels (pg / mL) in supernatant from T cells expressing fusion proteins of the invention cocultured (CC) with cancer cells or culturedalone (EO). Numbering is with respect to the WT CCL4 positioning after the 23 amino acid signal peptide.Mutation SEQ ID NO: Construct SEQ ID NO: CC EO WT 4 10 960 143 5668 58 F13A 138 10 1181 144 4862 76 cut6aa 139 10 1182 145 2180 54 L34A 140 10 1184 146 5636 76 allA 141 10 1185 147 3984 66AAWVA 142 10 1187 148 4248 80
[0270] Table 8: CCL3 mutations and IFNb levels (pg / mL) in supernatant from T cells expressing fusion proteins of the invention cocultured (CC) with cancer cells or cultured alone (EO). Numbering is with respect to the WT CCL3 positioning after the 23 amino acid signal peptide.SEQ SEQMutation ID NO: Construct ID NO: CC EOWT 3 10 959 151 2584 52Q33A 149 10 1175 152 3752 52AAWVA 150 10 1178 153 2216 48
[0271] Many of the mutations reduced background IFNb secretion (secretion in the absence of cancer cells) while retaining robust IFNb secretion when the T cells became activated. Finally, the AAWVA mutations while increasing secretion in the presence of cancer cells also increased background. The CCL4 and CCL3 mutations did not significantly reduce background secretion, but all were still effective and the Q33A mutation in CCL3 in particular raised IFNb secretion after activation. The results demonstrating the different effects of the various mutations of the chemokines relative to the wild-type chemokine background show that either the native protein or selected mutant variants may be used, depending on the intended application and the desired biological activity.Example 4: Testing in vivo efficacy of the constructs of the invention
[0272] For in vivo efficacy evaluation of the novel constructs of the invention, female SCID. Beige mice (aged 6-8 weeks, n=7 per group) were inoculated intraperitoneally (IP) on Day -8 with a tumor cell suspension containing 5 million SKOV3 human ovarian carcinoma cells. On Day 0 (8 days post-inoculation), mice were randomized into cages and treated by Adoptive Cell Transfer (ACT) with T cells expressing the HER2-CAR constructs with either the active immune sensor signaling pathway fusion protein of construct (10_510; IS-CAR; CCL5-MAVS_CARD3mut) or a non-active immune sensor control (10 745), alongside amedia control group. The T cells were IP injected at single doses of either 0.3 million (Fig.8A) or 0.5 million cells per mouse (Fig. 9B). Animals were closely monitored for clinical signs and body weight at least twice weekly throughout the 90-day study duration. Any abnormal clinical signs were recorded, and animals displaying severe clinical symptoms, a body weight reduction exceeding 20% from pre-test levels, or clear signs of morbidity were humanely euthanized in accordance with approved ethical guidelines. The results demonstrated a significant survival benefit with a single low -dose of IS-CAR cell treatment compared to inactive IS-CAR control. HER2-IS-CAR T therapy showed superior tumor control and significantly extended survival compared to media and inactive sensor groups (PO.OOOl at 0.3M; P=0.0019 at 0.5M). Notably, a subset of the 0.5M dose group survived through the Day 90 study endpoint and these were the only mice that survived until the end (Fig. 8B).
[0273] In vivo tests are also run with the other constructs of the invention and similar are observed. The fusion proteins of the invention effectively control tumor growth and enhance survival in vivo.Example 5: Testing additional CARS
[0274] The anti-HER2 CAR was used as a proof-of-concept and it will be readily apparent to a skilled artisan that any activating (classic) CAR will produce the same effect. Nevertheless, in order to render it fully clear that the particular CAR used is not what causes the effect, but rather that the CAR can be selected purely based on the target against which an immune response is to be activated, two additional CARs were tested. Commercially available CARs against the tumor antigens Lymphocyte Antigen 6 Family Member G6D (LY6G6D) and claudin 6 (CLDN6) were tested with fusion proteins of the invention.
[0275] A CCL5-MAVS_CARD3mut fusion protein separated from the CLDN6 CAR (construct 10 1072) and a CCL5_AAWVA mutant- MAVS_CARD3mut fusion protein separated from the CLDN6 CAR (construct 10 1076) were both tested in T cells cultured alone orwith CLDN6 expression OVCAR3 tumor cells. As expected, the constructs strongly secreted IFNb, but only when the cancer cells were presented (Fig. 9A). Further, as before the AAWVA mutation increased secretion at both the background level and after T cell activation via the CAR.
[0276] A CCL5-MAVS_CARD3mut fusion protein in a separate construct (plasmid) from the LY6G6D CAR (construct 10 938) and a CCL5-dead MAVS CARD (E26R) fusion protein separated from the LY6G6D CAR (construct 10 940) were both tested in T cellscultured alone or with LY6G6D expression HT55 tumor cells. The active fusion protein produced robust IFNb secretion only in the present of the cancer cells, once again demonstrating that the CAR is only needed for targeting (Fig. 9B). As expected, the dead MAVS did not produce significant IFNb.
[0277] CD 19 CAR alone or A CCL5-MAVS_CARD3mut fusion protein (10_502) coexpressed with the CD 19 CAR were tested in T cells cultured alone or with NALM6 cells expressing CD 19 antigen. The active fusion protein produced robust IFNb secretion in the present of the target cells, once again demonstrating that the CAR is only needed for targeting (Fig. 9C).Example 6:
[0278] To evaluate the therapeutic efficacy of CCL5-IFNb CAR-T cells, the inventors induce experimental autoimmune encephalitis (EAE) in 8-12 week-old female C57BL / 6 mice via subcutaneous immunization with 200ng Pertussis Toxin peptide emulsified in Complete Freund’s Adjuvant (CFA). Mice receive 200ng of Pertussis Toxin (PTX) intraperitoneally on Day 0 and Day 2 to facilitate blood-brain barrier permeability. Following the onset of clinical symptoms, mice undergo lymphodepletion via cyclophosphamide before receiving an intravenous infusion of 2-10 million CCL5-IFNb CD19-syngeneic CAR-T cells or control CCL5-GFP CD19-syngeneic CAR-T cells.
[0279] Clinical progression is monitored daily using a standardized 5-point scale to determine peak and cumulative disease scores. Primary readouts include flow cytometric analysis of CAR-T cell persistence and infiltration within the central nervous system (CNS). Additionally, histological examination of spinal cord tissue via Luxol Fast Blue and H&E staining quantifies the extent of demyelination and leukocyte infiltration. Finally, cytokine profiling of CNS homogenates via ELISA, identifies changes in the neuroinflammatory profile, specifically measuring levels of IFNg IL-17, and IL-10. A statistically significant reduction in the daily score compared to the control group is detected. A decrease in the number of perivascular "cuffs" (clusters of immune cells) invading the CNS tissue, typically visualized via H&E staining is seen in the treated group vs control.
[0280] Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
Claims
CLAIMS:
1. A fusion protein comprising a single polypeptide chain comprising a chemokine and a constitutively active protein of the immune sensor signaling pathway.
2. The fusion protein of claim 1, wherein said chemokine is selected from Chemokine (C-C motif) ligand 1 (CCL1), CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CXCL3, CCL9, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL2 and variants thereof.
3. The fusion protein of claim 1 or 2, wherein said chemokine is selected from CCL5, CCL4, CCL3 and variants thereof.
4. The fusion protein of claim 3, wherein said CCL5 comprises SEQ ID NO: 5 or a sequence with at least 85% sequence identity thereto, said CCL4 comprises SEQ ID NO: 4 or a sequence with at least 85% sequence identity thereto, said CCL3 comprises SEQ ID NO: 3 or a sequence with at least 85% sequence identity thereto or a combination thereof.
5. The fusion protein of any one of claims 2 to 4, wherein a variant targets said fusion protein to a non-lytic vesicle in a T cell and produces secretion of said fusion protein upon activation of said T cell.
6. The fusion protein of any one of claims 3 to 5, wherein said variant of CCL5 is a variant with reduced binding to heparin and comprises a sequence selected from SEQ ID NO: 45 and 49-64.
7. The fusion protein of any one of claims 3 to 5, wherein said variant is a variant of SEQ ID NO: 5 and comprises a sequence selected from SEQ ID NO: 106-121.
8. The fusion protein of any one of claims 3 to 5, wherein said variant is a variant of SEQ ID NO: 4 and comprises a sequence selected from SEQ ID NO: 138-142.
9. The fusion protein of any one of claims 3 to 5, wherein said variant is a variant of SEQ ID NO: 3 and comprises a sequence selected from SEQ ID NO: 149-150.
10. The fusion protein of any one of claims 1 to 9, wherein said protein of the immune sensor signaling pathway is selected from: cGAS, MAVS, IRF3, IRF7, MDA5, STING, RIGI, IFN-B and fragments and variants thereof.
11. The fusion protein of any one of claims 1 to 10, wherein said constitutively active protein of the immune sensor signaling pathway is selected from those provided in Table 2.
12. The fusion protein of any one of claims 1 to 11, wherein said constitutively active protein of the immune sensor signaling pathway is a fragment of Mitochondrial antiviral-signaling protein (MAVS) comprising a CARD domain.
13. The fusion protein of claim 12, wherein said constitutively active immune sensor signaling pathway protein comprises or consists of SEQ ID NO: 29 or a variant thereof that increases MAVS signaling.
14. The fusion protein of claim 13, wherein said variant comprises SEQ ID NO: 30 or SEQ ID NO: 154.
15. The fusion protein of any one of claims 1 to 11, wherein said constitutively active protein of the immune sensor signaling pathway is a truncation of cyclic GMP-AMP [cGAMP] synthase (cGAS) lacking its N-terminal domain.
16. The fusion protein of claim 15, wherein said immune sensor signaling pathway protein comprises or consists of SEQ ID NO: 46.
17. The fusion protein of any one of claims 1 to 11, wherein said constitutively active protein of the immune sensor signaling pathway is interferon beta (IFNb).
18. The fusion protein of claim 17, wherein said immune sensor signaling pathway protein comprises or consists of SEQ ID NO: 162.
19. The fusion protein of any one of claims 1 to 17, comprising an amino acid linker between said chemokine and constitutively active protein of the immune sensor signaling pathway.
20. The fusion protein of any one of claims 1 to 13 and 18, wherein said chemokine comprises or consists of an amino acid sequence selected from SEQ ID NO: 3-5, 106-121, 138-142 and 149-150 and said constitutively active immune sensor protein comprising or consisting of an amino acid sequence selected from SEQ ID NO: 30 and 154.
21. The fusion protein of any one of claims 1 to 19, wherein a sequence of the fusion protein comprises or consists of an amino acid sequence selected from SEQ ID NO: 37, 122-137, 143-148, 151-153 and 155-159.
22. The fusion protein of any one of claims 1 to 10, 14 to 15 and 18, comprising or consisting of SEQ ID NO: 65.
23. The fusion protein of any one of claims 1 to 10, 16 to 17 and 18, comprising or consisting of SEQ ID NO: 163.
24. A nucleic acid molecule encoding a fusion protein of any one of claims 1 to 22.
25. The nucleic acid molecule of claim 23, comprising a promoter operably linked to a first coding sequence encoding said fusion protein of any one of claims 1 to 22.
26. The nucleic acid molecule of claim 24, wherein said promoter comprises or consists ofSEQ ID NO: 66 or 67.
27. The nucleic acid molecule of claim 24 or 25, further comprising a 5’ untranslated region (UTR) between said promoter and said first coding sequence, a 3 ’ UTR 3 ’ to said first coding sequence, or both, optionally wherein said 5’ UTR comprises or consists of SEQ ID NO: 68, said 3’ UTR comprises or consists of SEQ ID NO: 69 or both.
28. The nucleic acid molecule of any one of claims 23 to 26, further comprising a second coding sequence encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR).
29. The nucleic acid molecule of claim 27, wherein said second coding sequence encodes a CAR.
30. The nucleic acid molecule of claim 27 or 28, wherein said CAR comprises an antigen binding domain that binds to a tumor antigen.
31. The nucleic acid molecule of claim 29, wherein said tumor antigen is selected from Receptor tyrosine-protein kinase erbB-2 (HER2 / ERBB2), claudin 6 (CLDN6) and lymphocyte antigen 6 family member G6D (LY6G6D).
32. The nucleic acid molecule of claim 30, wherein said tumor antigen is HER2 and said CAR comprises the antigen binding domain of trastuzumab.
33. The nucleic acid molecule of any one of claims 27 to 31, comprising between said coding sequence encoding said fusion protein and said second coding sequence encoding said CAR a furin cleavage site or a ribosomal skipping peptide, optionally wherein said ribosomal skipping peptide is selected from a P2A peptide, a T2A peptide, an E2A peptide and an F2A peptide.
34. The nucleic acid molecule of claim 32, comprising both a furin cleavage site and a T2A peptide between said first coding sequence and said second coding sequence.
35. An immune cell expressing at least one of:a) a fusion protein of any one of claims 1 to 22 and a CAR;b) a nucleic acid molecule of any one of claims 23 to 26 and a nucleic acid molecule encoding a CAR; andc) a nucleic acid molecule of any one of claims 27 to 33.
36. The immune cell of claim 34, being a T cell, a natural killer (NK) cell or a macrophage.
37. The immune cell of claim 35, being a CD 8 T cell or a CD4 T cell.
38. The immune cell of any one of claims 34 to 36, comprising upon forming an immunological synapse secretion of a type I interferon at a level that is at least 10 times higher than secretion by an immune cell that does not express any one of (a), (b) and (c).
39. The immune cell of claim 37, wherein said type I interferon is interferon beta (IFNb).
40. A pharmaceutical composition comprising at least one of:a) a fusion protein of any one of claims 1 to 22 and a CAR;b) a nucleic acid molecule of any one of claims 23 to 26 and a nucleic acid molecule encoding a CAR;c) a nucleic acid molecule of any one of claims 27 to 33; andd) an immune cell of any one of claims 34 to 38;and a pharmaceutically acceptable carrier, excipient or adjuvant.
41. A method of treating a disease treatable by activation of an innate immune response in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition of claim 39, thereby treating a disease treatable by activation of an innate immune response.
42. The method of claim 40, wherein said activation of an innate immune response is activation of a type I interferon response.
43. The method of claim 40 or 41, wherein said activation of an innate immune response is activation of an innate immune response against a cell expressing a target antigen and wherein said CAR binds said target antigen.
44. The method of any one of claims 40 to 42, wherein said disease is cancer.
45. The method of claim 43, wherein said cancer expresses a surface antigen that is bound by said CAR.
46. The method of claim 43 or 44, wherein said cancer is a solid cancer, optionally wherein said cancer is selected from breast cancer and ovarian cancer.
47. A method of designing an immune sensor signaling pathway fusion protein, the method comprising;a) selecting a coding sequence encoding a chemokine selected from CCL3, CCL4 and CCL5;b) selecting a coding sequence encoding a constitutively active protein of the immune sensor signaling pathway protein; andc) linking said selected coding sequence encoding a chemokine to said selected sequence encoding a constitutively active immune sensor protein via a peptide linker to produce a fusion protein;thereby, designing an immune sensor fusion protein.
48. The method of claim 46, wherein said linking comprises linking said coding sequence encoding a chemokine is N-terminal to said selected sequence encoding a constitutively active immune sensor protein.
49. The method of claim 46 or 47, further comprising expressing said produced fusion protein in an immune cell and measuring secretion of a type I interferon by said immune cell with and without activation of said immune cell and selecting a produced fusion protein that causes said immune cell to secretes at least 10 times more of said type I interferon when the immune cell is activated as compared to when it is not activated.
50. A method of generating a cytotoxic immune cell against a target antigen, the method comprising;a) designing an immune sensor fusion protein by a method of any one of claims 46 to 48;b) selecting a chimeric antigen receptor (CAR) against said target antigen; and c) expressing in a cytotoxic immune cell said designed immune sensor signaling pathway fusion protein and said selected CAR;thereby generating a cytotoxic immune cell against a target antigen.
51. The method of claim 49, wherein said method comprises producing a nucleic acid molecule comprising a promoter operably linked to a first open reading frame encoding said immune sensor fusion protein and a second open reading frame encoding said selected CAR and wherein there is a furin cleavage site or a ribosomal skipping peptide between said first open reading frame and said second open reading frame, optionally wherein said ribosomal skipping peptide is selected from a P2A peptide, a T2A peptide, an E2A peptide and an F2A peptide.
52. The method of claim 50, wherein both a furin cleavage site and a T2A peptide are between said first open reading frame and said second open reading frame.
53. A constitutively active immune sensor protein, comprising at least 85% sequence identity to SEQ ID NO: 29 and comprising a mutation at position 77.
54. The constitutively active immune sensor protein of claim 53, further comprising an N-terminal methionine residue.
55. The constitutively active immune sensor protein of claim 53 or 54, wherein said mutation at position 77 is mutation of glycine to lysine, arginine, histidine or glutamine.
56. The constitutively active immune sensor protein of claim 55, wherein said mutation at position 77 is mutation of glycine to lysine (G77K).
57. The constitutively active immune sensor protein of any one of claims 53 to 56, further comprising mutation of valine 81, serine 89 or both.
58. The constitutively active immune sensor protein of claim 57, wherein valine 81 is mutated to lysine, arginine or histidine; serine 89 is mutated to lysine, arginine or histidine; or both.
59. The constitutively active immune sensor protein of claim 57 or 58, comprising mutation of valine 81 to lysine (V81K) and mutation of serine 89 to lysine (S89K).
60. The constitutively active immune sensor protein of any one of claims 53 to 59, wherein constitutive activity comprises persistent activation of the TBK1-IRF3 pathway, optionally wherein constitutive activity is in the absence of cytoplasmic DNA.
61. The constitutively active immune sensor protein of any one of claims 53 to 60, comprising SEQ ID NO: 154 or a sequence with at least 85% sequence identity thereto.
62. The constitutively active immune sensor protein of any one of claims 53 to 61, comprising SEQ ID NO: 30 or a sequence with at least 85% sequence identity thereto.
